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Definitions related to a treatment
or procedure
Consensus
statement
instruction Symbol
Scientific evidence that a
treatment or procedure is
beneficial and effective.
Requires at least one
randomized trial, or is
supported by strong
observational evidence and
authors’ consensus (as
indicated by an asterisk).
‘Should do this’
General agreement and/or
scientific evidence favor the
usefulness/efficacy of a
treatment or procedure. May be
supported by randomized trials
based on a small number of
patients or not widely
applicable.
‘May do this’
Scientific evidence or general
agreement not to use or
recommend a treatment or
procedure.
‘Do not do this’
The categorization for our consensus document should not be considered
directly similar to theone used for official society guideline recommendations,
which apply a classification (I–III) and level of evidence (A, B, and C) to
recommendations.Introduction
Patients with cardiac diseases or conditions with high risk of
developing cardiac diseases undergo risk assessment by car-
diologists, primary care physicians, and scientists based on
referral for more advanced risk assessment strategies, institu-
tion of preventive treatments, counselling of patients and their
relatives, and selection of patients for scientific trials. The
various methods used for risk assessment differ with respect
to availability, complexity, and usefulness in different patient
populations. Parameters associated with increased risk of e.g.
death may also be associated with higher risk of other adverse
outcomes. However, risk assessment strategies including
specific methods for risk assessment and risk scores should
be used only for the purposes for which they are validated.
This expert consensus statement of the European Heart
Rhythm Association (EHRA), Heart Rhythm Society (HRS),
Asia Pacific Heart Rhythm Society (APHRS), and the Latin
American Heart Rhythm Society (LAHRS) summarizes the
consensus of the international writing group based on a thor-
ough review of the medical literature regarding risk assessment
in cardiac arrhythmias. To create a tool for clinicians to perform
rational and evidence-based risk stratification, this task force
was set downbyEHRA,HRS,LAHRS, andAPHRS, including
representatives from each of the four societies.
With this document, we intend to describe and review sta-
tus of performing risk assessment in different patient popula-
tions with cardiac diseases or conditions with high risk of
developing such. Our objectives are to raise awareness of us-
ing the right risk assessment tool for a given outcome in a
given population, and to provide physicians with practical
proposals that may lead to improvement of patient care in
this regard. For quick reference, sub-chapters start with a
short section on consensus statements. The document con-
cludes with a summary of consensus statements.Evidence review
Members of the Task Force were asked to perform a detailed
literature review using PubMed and EMBASE, weigh the
strength of evidence for or against a particular treatment or
procedure, and include estimates of expected health outcomes
forwhich data exist. Patient-specificmodifiers, comorbidities,
and issues of patient preference thatmight influence the choice
of particular tests are considered, as are frequency of follow-
up and cost-effectiveness. In controversial areas, or with re-
gard to issues without evidence other than usual clinical prac-
tice, consensuswas achieved by agreement of the expert panel
after thorough deliberations. This document was prepared by
the Task Force and peer-reviewed by official external re-
viewers representing EHRA, HRS, APHRS, and LAHRS.
Consensus statements are evidence-based and derived pri-
marily from published data or determined through consensus
opinion if no data available. Current systems of ranking level
of evidence are becoming complicated in a way that might
compromise their practical utility.1 In contrast to guidelines,
we opted for an easier user-friendly system of ranking using
‘coloured hearts’ that should allow physicians to easily assess
the current status of the evidence and consequent guidance
(Table 1). This EHRA grading of consensus statements
does not have separate definitions of the level of evidence.
The categorization used for consensus statements must not
be considered directly similar to the one used for official so-
ciety guideline recommendations which apply a classification
(Class I–III) and level of evidence (A, B, and C) to recom-
mendations used in official guidelines.
Nielsen et al Risk Assessment in Cardiac Arrhythmias e273Thus, a green heart indicates a ‘should do this’ consensus
statement or indicated risk assessment strategy based on at
least one randomized trial or supported by strong observa-
tional evidence that it is beneficial and effective. A yellow
heart indicates general agreement and/or scientific evidence
favoring a ‘may do this’ statement or the usefulness/efficacy
of a risk assessment strategy or procedure. A ‘yellow heart’
symbol may be supported by randomized trials based on a
small number of patients or not widely applicable. Risk
assessment strategies for which there is scientific evidence
of no benefit or potential harm and should not be used (‘do
not do this’) are indicated by a red heart.
Finally, this consensus document includes evidence and
expert opinions from several countries. The risk assessment
approaches discussedmay therefore include tests not approved
by governmental regulatory agencies in all countries.
Relationships with industry and other conflicts
All members of the writing group, as well as reviewers, have
disclosed any potential conflicts of interest. Details are avail-
able in supplementary material online.
All consensus statements were voted upon by the writing
committee independently and reached the predefined level
of 75% consensus for inclusion in consensus statement ta-
bles. Each partner society officially reviewed the document,
and all reviewer comments were addressed. Each partner
society approved the final document and consensus state-
ments.General tools for risk assessment, strengths,
limitations, and pretest probability
Value of clinical history and characteristics
including clinical risk scores such as CHA2DS2-VASc
Clinical assessment of the patient with cardiac arrhyth-
mias starts with a good clinical history and basic investi-
gations for an underlying etiological factor for the
arrhythmia or its associated complication(s). In addition,
an assessment of the risks and benefits of any therapeutic
intervention should be made, and appropriate management
initiated.
Following on from clinical history and assessment, there
is a proposal toward a more integrated and holistic approach
to arrhythmia management, as evident in guidelines. Such
an integrated approach requires multidisciplinary teams of
healthcare professionals, patient involvement, access to
treatment options, and decision-support tools to optimize
the patient journey. Many proposals have been made to-
wards the operationalization of such an integrated approach
to risk assessment and practical management in cardiac ar-
rhythmias, which has been of varying complexity. As an
example, the management of atrial fibrillation (AF) has
been simplified into the ABC pathway (‘A’ Avoid stroke
with Anticoagulation; ‘B’ Better symptom management,
with patient-centered and symptom-directed decisions on
rate or rhythm control; ‘C’ Cardiovascular and comorbidityrisk management), which has been shown to be associated
with improved clinical outcomes and reduced healthcare
costs.2–6
This makes a strong argument for using the right ap-
proaches and clinical tools for patient assessment, but using
them appropriately for the reasons they were first proposed
(e.g. stroke risk scores to assess stroke risk, and not other out-
comes).
Taking AF as an illustrative example with regard to using
the right score for the right reason there are many risk factors
for stroke (but the more common and validated ones have
been used to formulate risk stratification tools).7 The most
common in use is the CHA2DS2-VASc score,
8 but it is not
meant to include every possible stroke risk factor, and was
designed to be simple, reductionist and practical to help
decision-making for stroke risk. As with all clinical scores
based on clinical factors, the CHA2DS2-VASc score only
performs modestly for predicting high-risk patients who sus-
tain events. The use of more clinical factors and biomarkers
improves prediction (at least statistically), but the practical
added value is marginal and less impressive in real-world
cohorts.9,10 Use of simplified scores to artificially categorize
patients into low-, moderate-, and high-risk strata can be
problematic, as in the real-world patients do not necessarily
fall into three neat categories of risk. Also, not all risk factors
carry equal weight, hence, the move to focus the initial
decision-making on identifying low-risk patients who do
not need antithrombotic therapy first, following which stroke
prevention can be offered to AF patients with 1 stroke risk
factors.9 Stroke risk is also highly dynamic, and although
logistically challenging, a clinical reassessment may be
needed every 4–6months to optimize risk re-assessment.11–13
As the CHA2DS2-VASc is a cluster of common
cardiovascular risk factors, it is predictive of death,
cardiovascular hospitalizations, and other adverse outcomes
that the CHA2DS2-VASc score was not designed for. Also,
given that many components of the CHA2DS2-VASc score
are associated with incident AF, the CHA2DS2-VASc score
is used to predict new onset AF, again something it was not
designed for. Another misuse of the CHA2DS2-VASc score
is the prediction of bleeding risk. Nevertheless, formal
comparisons show that the CHA2DS2-VASc (and older
CHA2DS2) score are inferior to a formal bleeding risk
score such as the HAS-BLED score, for the prediction of ma-
jor bleeding in AF patients.14
Indeed, bleeding risk is also highly dynamic, and the
appropriate use of bleeding risk scores such as HAS-BLED
is to address modifiable bleeding risk factors (e.g. uncon-
trolled hypertension, labile INR, concomitant aspirin, or
NSAID use) then to schedule the ‘high-risk’ patients for early
and more frequent follow-up visits (e.g. 4weeks rather than
4months).15 Only focusing on modifiable bleeding risk fac-
tors is an inferior strategy for bleeding risk assessment,
compared to the HAS-BLED score.8
We should use the scores only for the purposes they were
designed for. Attention to appropriate methodology, statis-
tics, etc., as well as other clinical states, merits consideration
e274 Heart Rhythm, Vol 17, No 9, September 2020e.g. sudden death prediction (or failed ablation, device infec-
tion, etc.), Charlson Comorbidity Index, frailty, etc.—but us-
ing the right score designed for that purpose.
If appropriately used, some of these (simplified) tools help
with clinical management. Indeed, the value of a medical test
is measured by its accuracy as well as how it impacts medical
decisions and ultimately patient health. As medical tests are
considered and new ones emerge, they should be considered
and evaluated in a framework of accuracy and patient
impact.16 A test must not only be accurate, but also feasible.
Tests that are difficult to reproduce, subject to technical fail-
ures, or difficult to interpret are likely to impact patient care
as a consequence of a primary failure to produce a definitive
and actionable result.Electrocardiographic methods including
monitoringElectrocardiographic methods including
monitoring Class References
Twelve-lead electrocardiogram (ECG)
should be obtained in all patients
undergoing evaluation for known or
suspected heart disease.
17
The 12-lead ECG provides diagnostic and
prognostic information in patients with
inherited high-risk syndromes including
long QT syndrome (LQTS), short QT
syndrome, Brugada syndrome, and
arrhythmogenic cardiomyopathy (ACM)
and should be obtained.
17
Exercise ECG provides diagnostic and
prognostic information for patients
with LQTS ACM, hypertrophic
cardiomyopathy (HCM),
catecholaminergic polymorphic
ventricular tachycardia, and
documented or suspected arrhythmias
related to exertion, and should be
obtained.
17
Ambulatory ECG evidence of non-
sustained ventricular tachycardia
provides prognostic information in
ischemic cardiomyopathy, ACM, and
HCM and should be obtained.
17
The signal-averaged ECG and QRS
fragmentation may aid in the
diagnosis of ACM.
18
The signal-averaged ECG and QRS
fragmentation may be useful in risk
stratification of Brugada syndrome.
18
Heart rate variability, heart rate
turbulence, signal-averaged ECG, and
T wave alternans analysis, when used
in combination with additional
clinical, electrocardiographic, and
structural measures, may be useful for
identifying high- and low-risk groups
among patients with acquired
structural heart disease.
19Electrocardiographic methods
The ECG is the gold standard for risk assessment in patients
with or at risk of developing cardiac arrhythmias. The 12-lead
ECG is inexpensive and widely available. Risk stratification
with the ECG is limited in general by its low positive predic-
tive value (PPV) determined to a large extent by the low prev-
alence of cardiovascular events in the general population.
However, the prognostic significance of the ECG is enhanced
in patients with heart disease.P wave and PR interval
The prognostic value of P wave characteristics has been exam-
ined in subjects enrolled in clinical trials ofAF for prediction of
the development of AF, where maximum Pwave duration was
a significant independent risk marker for the development of
AF over 10 years.20 This observation was confirmed by epide-
miologic/population studies (including ARIC and the Copen-
hagen ECG studies) that showed increased risk of AF in
patients with prolonged P wave duration and PR interval pro-
longation,21–23 and summarized in a review by Nikolaidou
et al.24Moreover, a prolongedPwavedurationwas determined
as a sensitive predictor of post-operative AF in patients under-
going coronary artery bypass grafting (CABG).25 The defini-
tion of an abnormal P wave varies greatly depending on how
it is measured, and definitions vary depending on whether P
wave area, duration, terminal forces in lead V1 or signal-
averaged P wave are analysed. Abnormal P wave morphology
was associated with incident stroke in the Multi-Ethnic Study
of Atherosclerosis.26 The prognostic significance of PR inter-
val prolongation, which is variably defined as PR intervals
greater than 196–220ms, is controversial and depends on the
patient population studied. Most studies show that PR interval
prolongation is not associated with increased mortality in
healthy middle-aged individuals during medium term follow-
up.On the other hand, a number of reports showworse survival
in patients with suspected heart failure (acute and chronic) or
heart disease [coronary artery disease (CAD)]. Additionally,
PR prolongation and P wave prolongation predict increased
risk of AF and the greater degrees of PR prolongation and P
wave duration predicted higher risks of AF.27,28 An increased
PR interval is also associated with poor cardiovascular out-
comes in patients with AF.29 Several studies have shown that
PR prolongation in patients undergoing cardiac pacing or
receiving cardiac resynchronization therapy (CRT) is an inde-
pendent predictor of worse prognosis and lower probability of
reverse remodelling as well as an increased risk of AF, death,
and hospitalization.30,31 There are no data indicating whether
the degree of PR prolongation portends a worse outcome
compared to patients who have lesser degrees of PR prolonga-
tion, nor is there information on its prognostic value in acute
inferior wall myocardial infarction (MI).QRS, QT interval, and T-wave
Over the years, a number of ECG techniques have been
developed to assess risk of ventricular tachyarrhythmias
Nielsen et al Risk Assessment in Cardiac Arrhythmias e275(VTs). These have the advantage of being non-invasive and,
often, inexpensive. For almost all of these techniques, there
are conflicting data, and not one technique has proven bene-
ficial in patients with structural heart disease. Moreover,
studies have varied in their reporting of sudden arrhythmic
death vs. total mortality. Among the risk predictors shown
to have value are QRS widening and fragmentation, QT
prolongation, T-wave abnormalities, and ventricular ectopy.
Although the prognostic value of each ECG parameter in
isolation is limited, in combination with additional ECG,
imaging, and genetic testing, these parameters can contribute
to effective risk stratification.QRS
QRS prolongation has been associated with all-cause mor-
tality in heart failure patients, implantable cardioverter-
defibrillator (ICD) shocks, and inducibility of sustained
VT. QRS prolongation in patients on Class IC antiar-
rhythmic drugs is a predictor of pro-arrhythmia, and should
be monitored, particularly during exercise. QRS prolonga-
tion predicts risk in patients with myotonic dystrophy and
in Brugada syndrome. Additional prognostic information
from the QRS is obtained from the signal-averaged ECG,
which amplifies the QRS, averages multiple complexes to
reduce noise, and filters out the T-wave in order to detect
late potentials, and provides evidence of slow conduction
substrate that associates with risk of re-entry tachyarrhyth-
mias.17 The signal-averaged ECG has been used to detect
risk of ventricular arrhythmias in post-infarction patients,
ACM, and Brugada syndrome. Although its specificity is
limited, its negative predictive value is high, particularly
in survivors of inferior wall myocardial infarction. The
signal-averaged ECG is not useful in patients with underly-
ing bundle branch block. QRS fragmentation, which in-
cludes abnormally notched narrow and wide QRS
complexes, is associated with the presence of myocardial
scar and is also associated with mortality in patients with
cardiomyopathy and with Brugada syndrome.32 The pres-
ence of an unprovoked type 1 Brugada syndrome pattern
is associated with increased risk as is discussed later in the
document.QT interval
Measurement of the QT interval can be complicated by
QRS prolongation and by the need to correct for heart
rate, as has been described elsewhere.33 Despite these lim-
itations, prolongation of the heart rate-corrected QT inter-
val (QTc) has been associated with mortality in several
population studies.34,35 In congenital long QT syndrome
(LQTS), the length of the QT interval is a major predictor
of risk of cardiac events, including sudden cardiac death
(SCD). When initiating QT-prolonging drugs such as sota-
lol or dofetilide, a QT interval of 500ms or higher should
prompt reduction or discontinuation of the offending
drug(s).QT dispersion
This measure of ventricular repolarization heterogeneity is
typically defined from the 12-lead ECG as the QTmax 2
QTmin. It has been used to predict a wide variety of events,
including ventricular pro-arrhythmia, VTs, although the
sensitivity, specificity, and accuracy are poorly defined and
highly dependent on the patient population studied.36T wave
T wave inversions are common and may be non-specific or
may signal important abnormalities such as ischemia or hy-
pertrophy. Widespread deep T wave inversions in combina-
tion with QT prolongation, such as may occur in acute
stress cardiomyopathy, can be associated with torsades de
pointes. Abnormal T wave notching can be a clue to
abnormal repolarization and is often seen in patients with
QT prolongation. Computerized T-wave analytic techniques
such as principal component analysis, T-wave residuum, flat-
ness, asymmetry, and notching have been developed in an
effort to detect and quantify abnormal repolarization and
may have particular value in identifying patients with
LQTS.37,38 Moreover, it has been shown that adding T-
wave morphology characterizations to age, gender, and
QTc in a support vector machine model can improve LQTS
diagnosis.39 However, these additional analytic techniques
are not used in routine clinical practice.
The Tpeak-end interval, measured from the peak to the
end of the T-wave, thought to reflect heterogeneity of repolar-
ization in the heart, has been associated with arrhythmic risk
in various populations.40 However, considerable controversy
remains as to how it should be measured and applied.41
T-wave alternans is a beat-to-beat alternation of T wave
morphology.When seen with the naked eye, it usually accom-
paniesmarkedQTprolongation and is a harbinger of imminent
torsades de pointes. Analysis of more subtle T-wave alternans
has been used for assessing abnormal and heterogeneous repo-
larization to predict mortality and arrhythmic risk. Abnormal
microvolt T-wave alternans assessed using the spectral
method during graded exercise has a high negative predictive
value and has been used to identify a subgroup of patients with
reduced ejection fraction who are not likely to benefit from
defibrillator implantation.18 Microvolt T-wave alternans anal-
ysis cannot be performed when the rhythm is AF, and patients
with ventricular pacing have not been studied extensively.Early repolarization
Early repolarization pattern, highly prevalent in the overall
population, defined as an elevation of the J point of at least
0.1mV, may occur in the anteroseptal or inferolateral leads.
In 2008, Haissaguerre reported an association of inferolateral
early repolarization with increased risk of idiopathic ventric-
ular fibrillation (VF) in a case–control study42 and subse-
quently confirmed in other case–control studies. Exercise
testing or isoproterenol testing improved the pattern of repo-
larization, and the pattern was accentuated with exposure to
e276 Heart Rhythm, Vol 17, No 9, September 2020beta-adrenergic blockers. In a meta-analysis of population-
based studies, inferolateral early repolarization was associ-
ated with increased risk of arrhythmic death, but the risk
was still quite low in general (70/100 000 patient-years).43
It appears that individuals at highest risk have early repolar-
ization in multiple (especially inferior) leads, with high
voltage (at least 0.2mV), and with notching or horizontal/
down-sloping ST segments. Early repolarization is especially
prevalent in young men, particularly young black men, and in
athletes.44 Because the absolute risk of arrhythmic death is so
low, asymptomatic individuals with early repolarization,
even those with higher risk ECG patterns, do not require
further evaluation except when there is a strong family his-
tory of sudden cardiac death or when the J point elevation
is associated with Brugada syndrome (discussed later in
this document) or short QT syndrome (SQT).Ambulatory electrocardiographic monitoring
In 1984, Bigger et al. showed that ventricular ectopy recorded
on a Holter monitor, especially when combined with a low left
ventricular ejection fraction (LVEF), predicted a higher risk of
mortality in post-infarction patients compared to those without
ectopy.45 Non-sustained VT is also associated with increased
risk in patients with arrhythmogenic and hypertrophic cardio-
myopathy (HCM).Other data that can be extracted fromambu-
latory monitoring include heart rate, heart rate variability, and
heart rate turbulence measurements, which can predict mortal-
ity risk at least in ischemic cardiomyopathy (ICM), but have
not been incorporated into clinical practice.19,46ImagingImaging (echo, computed tomography
(CT), magnetic resonance imaging
(MRI), perfusion) Class References
Echocardiography should be used to
evaluate EF for risk assessment for
primary prevention of sudden cardiac
death and the presence of structural
heart disease. Alternatively, MRI or
cardiac CT can be used.
47,48
Cardiac MRI is useful in assessing
etiology-driven risk of VT and for the
presence of scar or myocardial
inflammation.
49–51
Cardiac positron emission tomography
may be useful for the assessment of
etiology-driven risk of ventricular
arrhythmias and the presence of scar
or myocardial inflammation in
patients without CAD.
52,53Risk assessment of ventricular tachyarrhythmia using imaging
modalities
Evaluation for the presence of structural heart disease
(SHD) is important for patients suspected of being at riskfor sudden cardiac death. Left ventricular ejection fraction
remains the key independent parameter for risk stratification
of sudden cardiac death and to guide implantation of an
ICD.47,48 Randomized controlled trials have shown a sur-
vival benefit from ICDs in patients with SHD and an EF
35%.54–56 Although EF is currently the only proven
imaging modality demonstrated to risk stratify for sudden
cardiac death, only 1–5% of patients with ICDs, implanted
based upon a low EF, require therapies each year and the
large majority of patients who receive ICDs will not have
ICD therapies over the 3-year period after implantation.57,58
In addition, up to 70% of all sudden cardiac deaths in the
community occur in individuals with EF .35%.58–60
Although the Efficacy of ICDs in Patients with Non-
ischemic Systolic Heart Failure (DANISH) trial showed
that primary prevention ICD in the setting of severe non-
ICM did not reduce all-cause mortality in patients on
optimal medical therapy for heart failure, ICD implantation
was associated with a 50% reduction in arrhythmic death. Of
note, within this non-ICM population, younger patients
(,68 years old) experienced a mortality benefit of 36% if
treated with an ICD.61
Ejection fraction is most readily evaluated with echocardi-
ography (recommendation level: green), given both lower
cost, availability of equipment, and available expertise; how-
ever, cardiac MRI or CT can also be used to evaluate EF and
SHD, particularly if obtained in combination of other assess-
ment aims, such as CAD or if there is controversy over the
quantified EF with echo (recommendation level: green).
The imaging modality used to estimate EF has not been
shown to determine benefit from ICD.48
Additional parameters beyond EF remain to be tested in
large studies. Cardiac MRI with late gadolinium enhancement
(LGE) can provide important prognostic information and may
allow for more accurate assessment of scar. Presence and loca-
tion of scar can portend a higher risk of sustainedVT.49–51,62,63
In a study of 452 non-ICM patients with New York Heart As-
sociation Class II or II and EF ,35%, ICD implantation was
only associated with reduced mortality in the population that
had presence of scar on cardiac MRI.64 Cardiac positron emis-
sion tomography (PET) may elucidate areas of inflammation
which may identify inflammatory cardiomyopathies and
sarcoidosis, a condition that is associated with higher risk of
ventricular arrhythmias in patients without CAD (increased
F-2-fluorodeoxyglucose uptake) or can be used to identify
sympathetic denervation (carbon-11-metahydroxyephedrine
imaging) or regions of inflammation. Greater sympathetic
denervation on PET in a prospective study of ICM patients
was a better predictor of ICD shocks than EF.65 Uptake of
iodine-123 meta-iodobenzylguanidine (MIBG) to evaluate
heart to mediastinum ration (H/M ratio) has shown mixed re-
sults in predicting arrhythmic death with some studies suggest-
ing additional prognostic benefit for this parameter, while
others have not demonstrated additional value.66,67 Impor-
tantly, the value of these additional parameters in determining
risk of sustained VT, VF, or benefit from ICD in various pop-
ulation remains to be clarified. Finally, routine use of viability
(Continued )
Invasive electrophysiological study
(EPS) Class References
EPS may be considered for risk
stratification of SCD in patients with
67,70,71,74
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reduce risk of SCD remains an area of investigation. In patients
with an EF ,35% and CAD amenable to revascularization,
routine use of PET to guide revascularization was not benefi-
cial in reducing overall mortality.68tetralogy of Fallot who have one or
more risk factors among LV
dysfunction, non-sustained VT and
QRS duration exceeding 180 ms.
EPS may be considered in patients with
congenital heart disease and non-
sustained VT to determine the risk of
sustained VT or identify SVT that could
be ablate.
67,70,71,74
EPS may be considered in asymptomatic
patients with spontaneous type 1
Brugada ECG pattern, or drug-induced
type 1 ECG pattern and additional risk
factors.
75–77
EPS is not recommended for additional
risk stratification in patients with
either long or short QT,
70,71Imaging modalities for atrial arrhythmias
Echocardiography (transthoracic or transoesophageal) is a
valuable tool in patients who present with atrial arrhythmias,
specifically atrial flutter and AF, to evaluate for the presence
of structural heart disease, left atrial enlargement, and
valvular heart disease in order to better define treatment
options. Cardiac MRI or CT may also be used if images
obtained at echocardiography are not reliable. However,
routine use of echocardiography, including atrial strain or
atrial function in patients who do not have atrial arrhythmias
to assess risk for the development of AF or atrial flutter is not
warranted, unless other structural cardiac abnormalities are
suspected.catecholaminergic VT or early
repolarization.
EPS is not recommended for risk
stratification in patients with
ischemic or non-ischemic DCM who
meet criteria for ICD implantation.
70,71
Invasive electrophysiological studyInvasive electrophysiological study
(EPS) Class References
EPS is indicated in patients with
syncope and previous myocardial
infarction, or other scar-related
conditions when syncope remains
unexplained after non-invasive
evaluation.
69
EPS may be considered in patients with
syncope and asymptomatic sinus
bradycardia, in a few instances when
non-invasive tests (e.g. ECG
monitoring) have failed to show a
correlation between syncope and
bradycardia.
70–72
EPS may be considered in patients with
EF 40%, without a primary
prophylactic ICD indication, and non-
sustained VT in ICM (MUSTT criteria)
to ascertain the presence of sustained
VT events.
73
EPS may be helpful in patients with
syncope and presence of a cardiac
scar, including those with a previous
myocardial infarction, or other scar-
related conditions, when the
mechanism of syncope remains
unexplained after non-invasive
evaluation.
66,70,71,73
EPS may be considered in patients with
syncope and bifascicular block, when
the mechanism of syncope remains
unexplained after non-invasive
evaluation.
67,70,71,74
(Continued )Currently, there are a few indications to perform an electro-
physiological study (EPS) to further assess the risk of arrhyth-
mias in at-risk cardiac patients. Such patients include those
with structural heart disease, LVEF.35%, pre-syncope, syn-
cope, palpitations, or markedly abnormal ECG suggesting se-
vere conduction disease. These patients can be considered for
an EPS to assess the risk of ventricular arrhythmias and sudden
cardiac death to decide on need of an ICD, or to identify con-
duction disturbances or supraventricular tachycardias that can
be treated with ablation or pacing.70,71
Patients with ICM without a primary indication for an
ICD, EF 40%, and non-sustained VT on ambulatory
cardiac monitoring are candidates for an EPS according to
the findings in the MUSTT trial,73 in which, 35% of patients
with inducible sustained VT had a significantly lower risk of
death with an ICD.66 The MADIT trial initially also utilized
an EPS in post-MI patients with an EF 30%, and non-
sustained VT events to implant an ICD, and showed survival
benefit with the ICD.54 However, MADIT-II subsequently
eliminated the need for an EPS in post-MI patients with
an EF 30% and similarly showed the life-saving benefit
of the ICD in a broader patient cohort.55 Therefore, post-
MI patients with an EF 30% do not currently need to
undergo an EPS to guide decisions on whether to implant
an ICD.
In patients with heart failure and EF 35%, an EPS is not
recommended for risk assessment for the decision on ICD
indication. Some centers perform an EPS for inducibility to
better characterize induced, sustained VT events, and their
e278 Heart Rhythm, Vol 17, No 9, September 2020response to anti-tachycardia pacing, which may potentially
help to tailor ICD programming. Furthermore, in patients
who have syncope of uncertain origin, an EPS could identify
ventricular arrhythmias or document electrical conduction
disorders.67,70,71,74
In the case of channelopathies, there is no indication for an
EPS, except for Brugada syndrome. In Brugada syndrome,
EPS may be useful in asymptomatic patients with sponta-
neous or drug-induced type 1 pattern, especially when there
is a family history of sudden death.75–77Implantable loop recordersImplantable cardiac devices Class References
An ILR is indicated in the evaluation of
patients with infrequent recurrent syncope
of uncertain origin especially when
ambulatory monitoring is inconclusive.
78–80
An ILR is indicated in patients with syncope
and high-risk criteria in whom a
comprehensive evaluation did not
demonstrate a cause of syncope or lead to a
specific treatment, and who do not have
conventional indications for primary
prevention ICD or pacemaker.
78–80
An ILR can be considered in patients with
palpitations, dizziness, pre-syncope,
frequent premature ventricular complexes
(PVCs)/non-sustained VT, and in those with
suspected AF, and following AF ablation.
78–80
Wearables/direct to consumer Class References
Wearables may provide diagnostic data
that contribute to disease detection
and management when integrated
into the clinical context and physician
judgement.
85,86
Table 2 High-risk and low-risk criteria for syncope at initial
evaluation (Adapted from 2018 ESC Guidelines for the diagnosis and
management of syncope82)
Syncopal events
Low-risk
Associated with prodrome typical or reflex syncope (e.g. light-
headedness, feeling of warmth, sweating, nausea, vomiting)
After sudden unexpected unpleasant sight, sound, smell, or paina
After prolonged standing or crowded, hot places
During a meal or postprandial
Triggered by cough, defecation, or micturition
With head rotation or pressure on carotid sinus (e.g. tumor,
shaving, tight collars)
Standing from supine/sitting position
High-risk
Major
New onset of chest discomfort, breathlessness, abdominal
pain, or headacheImplantable loop recorder to diagnose unexplained syncope/
atrial fibrillation with cryptogenic stroke
The implantable loop recorder (ILR) provides long-term
continuous monitoring and improves the diagnosis in pa-
tients with unexplained syncope.81 In a meta-analysis of 49
studies that included 4381 participants, the diagnostic yield
for the detection of arrhythmogenic syncope was 26.5%.78
Moreover, the CRYSTAL-AF trial80 revealed that the ILR
can detect subclinical AF following cryptogenic stroke. Still,
any benefit of these findings needs to be confirmed in large
randomized trials. Early use of the ILR has been advocated
by the European guidelines82 and in the American guidelines
following inconclusive non-invasive monitoring.83 The indi-
cations for ILR have been expanded in the current guidelines
(Table 2).Syncope during exertion or when supine
Sudden onset palpitation immediately followed by syncope
Presence of structural heart disease especially left ventricular
dysfunction and/or history of myocardial infarction
Minor (high-risk only if associated with structural heart disease or
abnormal ECG):
No warning symptoms or short (,10 s) prodrome
Family history of sudden cardiac death at young age
Syncope in the sitting position
ECG, electrocardiogram; VF, ventricular fibrillation.
aSudden loud sounds (as an alarm clock) may trigger VF in some long QT syn-
drome patients.Implantable loop recorder to diagnose atrial and ventricular
arrhythmia events
While the ILR can be useful to detect atrial and ventric-
ular arrhythmias, a large cohort study indicated that most
of the current use of ILRs is primarily in patients with
unexplained syncope (84%), followed by palpitations
(13%), and suspected AF (12%).79 Another smaller study
specifically studying the risk of SCD and arrhythmias inpatients with hemodialysis, found that 20% of these pa-
tients had SCD or bradyarrhythmia events necessitating
pacemaker implantation, and 33% of these patients had
an arrhythmic endpoint. Interestingly, the median time
to event was 2.6 years, confirming the need for long-
term monitoring. Surprisingly, however, bradyarrhythmias
were very commonly diagnosed in this cohort suspected
to be at high risk for ventricular arrhythmias and sudden
cardiac death.84 Further studies are needed to establish the
role of ILR in risk stratification.
Wearables/direct to consumerThe direct to consumer or wearable technology market,
comprised of devices that monitor physiological parameters
such as heart rate and sleep pattern, is anticipated to grow to
929million connecteddevices by2021.87These devices encom-
passwristbands, glasses, in-earmonitors, chest straps, and smart
phone-enabled recording electrode systems or electronic shirts,
Biomarkers, tissue, genetics Class References
Genetic testing should be
considered in several inherited
arrhythmic diseases associated
with an increased risk of
ventricular arrhythmia and
SCD.
95–97
MRI with LGE to detect fibrosis
and scar may be useful in
assessing the risk of arrhythmic
events in AF patients and
patients with
cardiomyopathies.
98–100
Plasma NT-proBNP may be useful
in differentiating patients
with higher vs. lower burden
of AF.
101–105
Plasma CRP or other inflammatory
markers may be useful in risk
assessment, for identifying
individuals with increased risk
of future AF and for identifying
individuals with high degree of
atrial fibrosis.
106–108
Nielsen et al Risk Assessment in Cardiac Arrhythmias e279with varying capacity to monitor heart rate, heart rhythm, blood
pressure, physical activity, respiratory rate, blood glucose, and
sleep patterns.88–90 For heart rate monitoring, most wearable
devices use photoplethysmography (PPG) technology,
meaning they are inherently less accurate than conventional
electrocardiography monitoring techniques. Accuracy of
various devices varies, with correlation to reference standard
ECG monitoring ranging from 0.76 to 0.99.91 Recent advances
in wearable ECG acquisition include use of direct electrode
recording that represents a regulatory approved medical device
generating a lead I like rhythm strip, blurring the lines between
consumer and medical devices.92
A growing body of evidence suggests that these tech-
nologies can be harnessed to facilitate arrhythmia detec-
tion in the appropriate context. Although marketed as
consumer devices, many wearable devices may generate
health data comparable to that of medical grade ECG
monitors, with several devices migrating to approved
medical use.85 Despite this promise, there are clear con-
cerns regarding accuracy, particularly false positives in
asymptomatic patients where device-based alerts can
raise unwarranted concern and generate low yield
screening for disease, with associated costs. Wearable
technologies represent an important frontier in health
evaluation, with the potential to provide readily acces-
sible health data for large segments of the population,
including those not captured by conventional monitoring
techniques. Though intended for personal use focused on
health promotion and physical activity, wearable technol-
ogies promise to invert the traditional paradigm of
healthcare delivery, with data collection and health
queries often initiated by consumers and not providers.
Providers may see wearables as accessible risk stratifica-
tion tools for detection of AF in high-risk cohorts (such
as high CHADS2-VASC2 score patients), and patients
may equally present for evaluation after device-based ob-
servations that call into question whether they are at risk.
The confluence of these factors is illustrated in the
recently presented Apple Heart Study, wherein 419 297
participants were recruited in only 8months to partici-
pate in an AF screening study that deployed a PPG-
based algorithm followed by a 7-day patch if AF was
suspected.93 Using a complex tachogram algorithm,
2126 individuals were sent irregular pulse notifications
and prompted for a telemedicine visit and 7-day ECG
patch. The authors reported a PPV of 84% for each
irregular pulse notification, and 71% for each irregular
tachogram. The burden of notifications and the perfor-
mance of the technology showed promise to inform
AF detection in the broader public. Similarly, the Hua-
wei Heart Study evaluated 187 912 individuals that
used smart devices to monitor their pulse rhythm, with
notification of suspected AF in 424 participants, with a
strong relationship between advancing age and detecting
AF. The predictive value of the algorithm in the 62% of
notified participants that pursued medical evaluation was
promising (87%).94Studies evaluating PPG-based wearables in conjunction
with machine-learning algorithms have shown promise in
arrhythmia detection, such as AF.86 Studies to date have
not focused on ventricular arrhythmia detection. Future wear-
ables will benefit from improved reliability and accuracy,
collect additional health and fitness parameters, support
chronic disease management, and provide real-time connec-
tivity and feedback that may supplant conventional medical
monitoring. Wearables have the potential to become truly
disruptive in our healthcare sector, with large segments of
the population accessing cardiac monitoring that the physi-
cian must interpret. Currently, we have no data on how the
information provided by PPG-based wearables will affect
management and outcomes of patients, or how risk scores
derived in other populations such as the CHA2DS2-VASc
score apply in these previously undetected subjects.Biomarkers, tissue, geneticsThe use of biomarkers, tissue biopsy, and genetic assess-
ment can be used for risk assessment in patients suspected of
specific arrhythmias or syndromes. The utility of using these
tools broadly spans determining arrhythmic risk, refining a
clinical diagnosis and estimating prognosis.Biomarkers
Cardiac myocytes express and secrete natriuretic hormones
that have a central function on blood pressure regulation,
blood volume, and plasma sodium balance. Levels of B-
type natriuretic peptide (BNP) and its stable N-terminal pep-
tide pro-BNP (NT-proBNP) are increased in AF.101 AF
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proBNP.102 In a large meta-analysis consortium, BNP and C-
reactive protein (CRP) associate with AF but only BNP was
superior to well-known clinical variables in AF risk predic-
tion.103 Inflammatory processes and fibrosis are central to
pathogenesis of AF,106,109 and the inflammatory marker
CRP is associated with longer AF duration and atrial remod-
elling.110 CRP levels are elevated in patients with permanent
AF compared to persistent AF patients and are predictive of
recurrent AF after catheter ablation,111,112 indicating that
CRP levels can be used to identify AF subtypes and evaluate
prognosis. Higher levels of CRP correlated to an increased
risk of developing AF in general and after acute myocardial
infarction.107,113 Similarly, the plasma protein YKL-40
may have diagnostic and prognostic use in AF patients108
because plasma serum chondrex (YKL-40) is associated
with atrial fibrosis severity in patients with lone AF.114 Pa-
tients who experience recurrent AF following ablation have
significantly increased YKL-40 baseline levels, although
plasma YKL-40 is not an independent predictor of recurrent
AF.108,115 Increasing levels of YKL-40 have been shown to
associate with a two-fold increased risk of future AF.116
Other simple AF biomarkers include body weight and blood
pressure, which are also major intervention targets.117–122Tissue diagnostics
Tissue diagnostics can be beneficial to differentiate various
infiltrative myopathic processes that can contribute to the
risk for arrhythmic events. Fibrosis and scarring are
well-recognized substrates for arrhythmia both in atria and
ventricles.109 Fibrosis may be assessed in atria as well as in
ventricular myocardium and its quantification can be used
in evaluating the risk of arrhythmia in AF and cardiomyopa-
thies.98,99 Specific patterns of scarring can assist in refinement
of the diagnosis for infiltrative myopathies, hypertrophic
cardiomyopathy, sarcoidosis, ACM, and amyloidosis. The
development and validation of advanced imaging techniques
including bio-metabolic imaging (sarcoid), and contrast
enhanced cardiac MRI (amyloid) have largely replaced the
need for invasive diagnostics.Genetics
The majority of clinically applicable genetic testing is in-
tended to be driven by phenotype and the pre-test probability
of specific diagnosis determines the utility of genetic investi-
gation.95 Due to incomplete penetrance of genetic arrhythmia
syndromes, harbouring a genetic variant with known patho-
genicity is almost never solely enough to meet diagnostic
criteria for a particular syndrome.123
For LQTS, part of the diagnostic framework (along with
the ECG biomarker of QT prolongation) can include a posi-
tive genetic test.123 Moreover, understanding the genetic
diagnosis is important for treatment and prognostication.
For example, patients with Jervell and Lange-Nielsen and
Timothy Syndrome patients (LQT8) have more malignant
clinical courses,124,125 and for LQT1 the arrhythmic riskdepends partly on which region of the channel the mutation
affects.126 In catecholaminergic polymorphic ventricular
tachyarrhythmia (CPVT),127 genetic testing of suspected in-
dividuals has a moderately high yield.95 Identification of an at
risk first-degree relative of a CPVT affected individual is
essential due to the high penetrance but more so the lethality
of this syndrome.123,128 Similar to LQT1, CPVT due to
RYR2 mutations may have some degree of risk depending
on where in the ryanodine receptor the mutation falls.129
Brugada syndrome can be particularly difficult to clinically
diagnose and the utility of genetic testing for improving diag-
nosis is poor. For patients who are clinically diagnosed with
Brugada syndrome the yield of genetic testing is w30%,130
the majority of whom harbor SCN5a mutations, a gene asso-
ciated with a plethora of arrhythmia syndromes.131,132
Genetic testing can be useful for family members of an appro-
priately genotype identified proband but is not recommended
in the absence of a diagnostic ECG.95 Using genetics as part
of diagnostic criteria for arrhythmogenic cardiomyopathies
will be discussed later in the document. Lastly, genetics in
AF is a developing area, but certain primary electrical sudden
death syndromes have increased AF association as discussed
in patients with inherited rhythm disease (long QT syndrome/
short QT syndrome/catecholaminergic polymorphic ventric-
ular tachyarrhythmia/Brugada syndrome) section. For fam-
ilies with a substantial number of AF cases or in early
onset AF,133–136 genetic testing can be considered but the
yield is low.Artificial intelligence
Machine learning is a broad term of artificial intelligence
derived from the extraction of patterns from large data sets.
The marriage with healthcare analytics and decision pro-
cesses has been rapidly forwarded with computerized medi-
cal records and the creation of large data warehouses.
A deep neural network was created to analyse raw ECG
data from an ambulatory heart monitor and classify it into
12 categories based upon the presence of arrhythmia. Ma-
chine learning performed very well with an average under
the reviewer operating characteristic curve (ROC) of 0.97
and an average F1 score (mean of the PPV and sensitivity)
of 0.837; a score better than an average cardiologist
(0.780).137
Machine learning has been applied to standard ECG char-
acteristics in sinus rhythm to predict incident AF using the
eight independent ECG leads (leads I, II, V1–6) through a
convolutional neural network.138 The ROC area under the
curve for the detection of AF was 0.87 (0.86–0.88) using
the internal validation dataset and 0.87 (0.86–0.88) using
the testing dataset.
In an analysis of the Atrial Fibrillation Prediction Data-
base, a machine learning approach based upon heart rate vari-
ability predicted onset of AF with sensitivity of 100%,
specificity of 95.6%, and accuracy of 96.2%.139 Machine
learning based upon ECG characteristics identified left ven-
tricular dysfunction with an area under the curve of 0.93,
Nielsen et al Risk Assessment in Cardiac Arrhythmias e281sensitivity of 86.3%, and specificity of 85.7% including risk
of left ventricular dysfunction in those without.140
Machine learning has shown accuracy in predicting mor-
tality and risk stratification of patients with CAD.141Machine
learning has also been shown to accurately discriminate be-
tween athletic hearts compared to hypertrophic cardiomyop-
athy hearts.142 Machine learning has great potential in this
area of risk assessment because of the large amount of data
contained in the large ECG and clinical datasets available
to determine rules.How to assess risk for atrial fibrillation in
specific populations
Patients of advanced age
There is agreement that the prevalence of AF in the general
population in the Western world is in the order of
1–2%.143–145 It is estimated that in 2010 there were 33.5
million people in the world with AF of which 20.9 million
were men and 12.6 million were women.146 During the past
20 years, the age-adjusted prevalence rates of AF increased
for bothmen andwomen and similarly the corresponding inci-
dence rates have increased.146–150Age is amajor risk factor for
the development of AF and in persons younger than 55 years a
prevalence ofAFaround0.5% is seenwhereas in personsolder
than 85 years AF prevalence is around 15% (Figure 1).144 A
stepwise increase in AF prevalence with increasing age has
been found in several studies.152,153 Studies in a multi-ethnic
cohort from the United States has shown large variation in18
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Figure 1 A depiction of the atrial fibrillation prevalence distribution found by eac
of AF prevalence, grouped by age. The thick line represents average AF prevalence
weighted by sample size. (Adapted from Andrade et al. Circ Res 2014.) AF, atrialAF prevalence among various race-ethnicity groups in which
AF associated hospitalizations were lower in Hispanics, Chi-
nese, and black Americans compared to white Americans.153
The predominant contributor to the increasing AF prevalence
is our aging populations, morewidespread use and availability
of screening tools, and improved treatment for various heart
diseases that enhance longevity.
Among AF patients, those aged younger than 65 years are
in general healthier than those older than 65 years.154 Life
time risks of AF in 55-year-old subjects without a history
of AF have been found to be 20–24% in the Rotterdam
study155 but considerably higher at 37% in the Framingham
study.134 The lifetime risk of AF in Asians older than 20 years
(1 in 6 for men and 1 in 7 for women; i.e. 14–17%) was lower
than the risk reported from Western countries.156
The incidence rates, prevalence, and lifetime risk of AF are
higher formen thanwomen.Despite this, the absolute number
of women with AF exceeds the total number of men with AF
because women live longer than men.144 Women have their
first episode of AF about 5 years later than men and less
commonly have lone AF.144 In general, women with AF are
more likely to have hypertension or valvular heart disease
compared to men.144 Women often present with atypical
symptoms related to AF (Figure 2). On the other hand,
compared to men, women are less likely to have asymptom-
atic AF, they have a higher symptom burden, they have higher
average heart rate duringAF andmore often longer lasting ep-
isodes of AF.144 These factors contribute to the observation
that women are more likely to contact their physician due to
AF-related symptoms compared to men.65-69 70-74 75-79 80-84 >85
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Investigations needed to assess
risk for AF in patients with heart
failure Class References
Cardiac MRI may be considered in
identifying degree of atrial
fibrosis and scar.
163
Use of biomarkers may be
considered for identifying
individuals with increased risk
of future AF and for identifying
individuals with high degree of
atrial fibrosis.
107,164,165
Searching for common genetic 166
e282 Heart Rhythm, Vol 17, No 9, September 2020Conflicting results exist with respect to risk of stroke sec-
ondary to AF and its prognosis in women compared to
men.157–159 There does not seem to be a gender difference
with respect to development of dementia secondary to AF,
although women have higher rates of dementia than men in
general.145,157
Since both AF and stroke are highly associated with age
and stroke may occur as a complication of AF it seems
reasonable to consider screening for this arrhythmia in
elderly populations. Several studies are ongoing and ex-
pected to be finalized within the next couple of years. These
studies are expected to guide us with respect to cost-
effectiveness of these screening strategies.variants associated with AF risk
by genetic molecular analysis
has not been found to be useful
in a routine clinical setting.Patients with heart failureInvestigations needed to assess
risk for AF in patients with heart
failure Class References
A careful evaluation of clinical
characteristics known to be
associated with increased risk
for AF should be performed.
160
Frequent interrogation or remote
monitoring of stored
arrhythmia episodes in device
implanted HF patients should
be performed in order to
diagnose AF and allow its early
management.
161
Echocardiography is useful in
identifying cardiac
characteristics associated with
a higher risk for AF.
162Due to common risk factors like age, hypertension, dia-
betes, obesity, and sleep apnea, AF and HF are intricately
linked and share common pathophysiologic mechanisms.
Atrial fibrillation occurs in more than half of individuals
with HF and presence of both carries greater mortality risk
compared with those without either condition.167
In the particular case of cancer treatment, HF is also a
common consequence of cardiotoxicity associated with
some chemotherapeutic agents, including anthracyclines,
human epidermal growth factor receptor 2 (HER2), and pro-
teasome inhibitors. In this setting, isolated cases of AF have
been reported. Even if the exact mechanism of these arrhyth-
mias induced by such drugs remains largely unknown, it
seems plausible that the negative effect on the cardiac systolic
function also plays a central role.168
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Nielsen et al Risk Assessment in Cardiac Arrhythmias e283Given the deleterious effects of AF in HF patients, signif-
icant interest has been directed to risk factors predicting the
development and progression of this arrhythmia (Figure 3).Clinical risk factors
Older age andmale gender are associated with a higher risk of
developing AF.160 Diabetes confers a 1.4- to 1.6-fold higher
risk for AF.160 Because of its high prevalence in the general
population, hypertension is responsible for more AF in the
population (14%) than any other risk factor.160 Obesity and
sleep apnea are independent risk factors for AF.169 AF inci-
dence also increases in case of renal or thyroid dysfunc-
tion.170,171
With regard to HF and the type of underlying heart dis-
ease, prevalence of AF increases significantly with the
severity of HF symptomatology. Among the valvular dis-
eases, the left-sided valve stenoses have the highest preva-
lence rates of AF. In addition, the presence of CAD or
hypertrophic cardiomyopathy is a significant risk factor for
incidence and progression of AF.172 Finally, in congenital
heart disease patients, substantial AF rates appear decades
before their onset in the general population.173Electrocardiography
Electrocardiogram-derived variables, such as the PR interval,
ECG-based left ventricular hypertrophy (LVH), P wave
indices like P wave duration, area, and terminal force have
been used in various AF prediction models but their additive
value over other clinical risk factors is minimal.174 Short
duration Holter monitoring is not useful for AF detection in
asymptomatic patients. Longer duration monitoring with
external or implantable loop recorders may help when parox-
ysmal AF is suspected. In addition, frequent interrogation orremote monitoring of Holter memories in device implanted
HF patients is mandatory in order to diagnose AF and allow
its early management.161Biomarkers
Markers of inflammation (high-sensitivity CRP, fibrinogen),
atrial overload (atrial and B-type natriuretic peptides),
myocardial ischemia (high-sensitivity troponin T and I), car-
diac fibrosis (galectin-3), and others (soluble ST2, growth
differentiation factor-15), have been studied to predict AF
incidence.165 Of these, only natriuretic peptides have consis-
tently demonstrated added predictive value beyond informa-
tion on clinical variables.164,165Imaging
Many echocardiographic variables have been associated with
a significantly higher AF recurrence rate. Possibly, left atrial
volume is superior to left atrial diameter in predicting pro-
gression to persistent AF. Speckle left atrial strain and stiff-
ness index can also predict the maintenance of sinus
rhythm after cardioversion for AF.162
Concerning MRI, the amount of left atrial enhancement
quantified on MRI with LGE may be helpful to predict pro-
gression of AF,163 but the reproducibility of such findings re-
mains controversial.Genetics
A family history of AF in a first-degree relative indepen-
dently increases AF risk two-fold.175 Recent research has
identified several common genetic variants associated with
the risk of AF.136 Further studies are required to evaluate
whether genetic information improves our ability to predict
AF on top of clinical variables.
e284 Heart Rhythm, Vol 17, No 9, September 2020Risk assessment of AF in patients with HF can be carried
out at first by considering the clinical features, comorbidities,
and underlying etiologies. It can be further refined by more
sophisticated investigations.Patients with obesity, hypertension, diabetes,
sleep apnea, or structural heart diseasePatients with obesity, hypertension,
diabetes, sleep apnea, or structural
heart disease Class References
Clinical risk factors should be assessed to
help identify incident AF and its
complications.
176
Clinical risk scores may be useful to
identify risk for incident AF.
177–179The assessment of underlying AF in people at higher risk
for AF can be considered from opportunistic perspective, or
the consideration of clinical risk prediction tools.180 Many
patients with common conditions that may predispose to
AF, such as obesity, sleep apnea, hypertension, or SHD
should or would be attending specialist clinics for their
assessment and/or follow-up. Hence, an opportunistic strat-
egy of pulse palpation and clinical assessment (e.g. symp-
toms) followed by appropriate ECG monitoring to confirm
AF would be an appropriate and cost effective method for
screening.181 In general, clinical scores have been less useful
as most only have modest predictive value for identifying the
population at risk; ultimately, these patients would also
require their AF documented. A strategy of using risk scores
to target high-risk patients for more intense screening efforts
merits consideration.
The systematic review by Allan et al.176 found that in rela-
tion to the relative risk of incident AF:
 For every 1–10 kg/m2 increase in body mass index (BMI),
or BMI 25–30 kg/m2, all 19 reports showed significant
direct associations (from 1.04 [1.02–1.05] to 2.24 [1.41–
3.58]).
 For every 10–22 mmHg increase in systolic blood pres-
sure, or systolic blood pressure160 mmHg, most reports
showed significant direct associations (from 1.14 [1.05–
1.25] to 2.63 [1.83–3.78]).
 For diabetes mellitus (type unspecified), eight reports
showed a direct but non-significant (from 1.02 to 1.49)
and six reports showed significant direct associations
(from 1.17 [1.16–1.19] to 1.80 [1.30–2.60]).
Many of these conditions are present concomitantly.
Also, obesity and hypertension are commonly associated
with sleep apnea, which is another risk for incident AF.
Obesity has been associated with incident AF,182 but clin-
ical trial data have a suggestion of an ‘obesity paradox’whereby overweight AF patients tended to have improved
outcomes; however, the relationship between obesity and
outcomes from real-world observational cohorts are less
clear.183–185 In a systematic review of trial and real-world ev-
idence, there was suggestion of an obesity paradox in AF pa-
tients, particularly for all-cause and cardiovascular death
outcomes.184 An obesity paradox was also evident for
stroke/systemic embolic event outcomes in the non-vitamin
K antagonist oral anticoagulant (NOAC) trials, with a
treatment effect favoring NOACs over warfarin for both effi-
cacy and safety that was significant only for normal weight
patients. Nonetheless, proactive management of obesity is
part of the lifestyle advice for patients with AF.
On a population basis, hypertension is the most common
etiological factor for AF, and contributes to its complications.
Indeed, AF can be regarded as a manifestation of hyperten-
sion target organ damage. The optimal blood pressure targets
in AF patients have been described, being 120–129/
,80mmHg.186 Also, longer hypertension duration is associ-
ated with the increased risk of ischemic stroke; however, this
long-term effect of hypertension duration can be attenuated
by long-term strict SBP control throughout the entire dura-
tion of hypertension.187
Poor diabetes control is associated with incident AF. In the
diabetic AF patient, longer disease duration is related to a
higher risk of stroke/thromboembolism in AF, but not with
a higher risk of anticoagulant-related bleeding.188 These risks
were similar for Type 1 and Type 2 diabetes.189 Evidence of
other target organ damage such as diabetic retinopathy
increased risk, although it did not add to the predictive value
of risk assessment using the CHA2DS2-VASc score.
190
Indeed, the ATRIA study also confirmed that duration of dia-
betes is a more important predictor of ischemic stroke than
glycemic control in patients who have diabetes and AF.191
Unsurprisingly SHD is a potent risk factor for incident AF,
as well as its complications, such as stroke and HF.177,192
Systolic HF is one of the components of the simple
C2HEST score [Chronic obstructive pulmonary disease and
CAD [1 point each]; hypertension [1 point]; elderly [age
75 years, 2 points]; systolic HF [2 points]; thyroid disease
[hyperthyroidism, 1 point])] which has been derived and vali-
dated in a large cohort of AF patients.177 This score could
potentially be considered to target the high-risk patients
that may be suited for more intense screening for incident
AF, e.g. post-stroke where the C2HEST score was superior
to the other scores such as the Framingham score.178 The
risks of AF with associated valvular heart disease are well
recognized, as recently discussed in an EHRA position
document.193 In terms of HF, there is a link between AF com-
plications and HF, whether HF with a reduced EF (HFrEF) or
HF with a preserved EF (HFpEF).194 In the CHA2DS2-VASc
score, the ‘C’ component refers to recent decompensated HF,
irrespective of the EF, or the presence of moderate-severe
systolic dysfunction whether asymptomatic or not.7 Of
note, the CHA2DS2-VASc score is predictive of stroke in
HF, whether or not AF is present.195
Nielsen et al Risk Assessment in Cardiac Arrhythmias e285Patients who have undergone cardiac surgeryPatients who have undergone cardiac
surgery Class References
Heart rhythm monitoring for 4–7 days is
recommended for detection of post-
operative AF.
196–198
Patients with post-operative AF may
undergo follow-up rhythm monitoring
to assess for the presence of
symptomatic and asymptomatic
arrhythmias.
196–199
Patients with cryptogenic stroke Class References
Patients should initially undergo brain
diffusion-weighted MRI imaging for
the diagnosis of cryptogenic stroke.
204,205
AF is more likely to be detected after
cryptogenic stroke with more intense
investigation with longer and more
sophisticated monitoring.
205–207
Long-term ECG monitoring techniques,
such as trans-telephonic ECG
monitoring or cardiac event recorders
or ILR, can increase yield of AF
diagnosis after cryptogenic stroke in
selected patients.
205,206
The use of an ILR should be considered
for detecting AF in selected patients
who are at higher risk of AF
development, including the elderly,
patients with cardiovascular risk
factors or comorbidities.
80,207
TOE may lead to the reclassification of
cryptogenic stroke because many
cases are embolic and due to a
cardiogenic source, mainly AF.
205,206Post-operative AF remains the most common complica-
tion following cardiac surgery and its incidence ranges be-
tween 20–50% across numerous studies.196 This risk
increases from isolated CABG surgery, to valvular surgery,
and in turn to concomitant CABG/valvular surgery.
Risk factors for developing AF may be divided into proce-
dural- andpatient-related factors. Procedural-related risk factors
include type of surgery, mitral valve surgery, use of intra-aortic
balloon pump, longer cardiopulmonarybypass andaortic clamp
times, and perioperative issues such as inflammation, infection,
fluid overload, inotropic use, atrial ischemia, hypokalemia,
and hypomagnesemia. Patient-related risk factors include
advanced age, history of AF, history ofHF, renal failure, hyper-
tension, chronic obstructive pulmonary disease, post-operative
withdrawal or absence of beta-blocker, or angiotensin-
converting enzyme inhibitor (ACE inhibitor) therapy.197,200
Left atrial remodelling predisposes to post-cardiac surgery
AF, with risk factors such as enlarged left atrial size, diastolic
dysfunction, LVH, obesity, obstructive sleep apnea, and the
CHADS2 and CHA2DS2-VASc score further predisposing to
post-operative AF.197,201,202
The majority of post-cardiac surgical AF occurs within the
first 4 post-operative days, and is most common on the 2nd
post-operative day, while recurrences are most common on
the 3rd post-operative day.197,203 In another study of
CABG patients, 94% of post-operative AF occurred by the
7th post-operative day.198 Hence rhythm monitoring such
as inpatient telemetry or ECG for post-operative AF should
focus on this time frame.
While post-cardiac surgical AF likely occurs as a result of
the interaction between acute perioperative triggers and the
underlying atrial and cardiac substrate, its occurrence iden-
tifies a subset of patients associated with long-term morbidity
and mortality. In a study of patients who underwent CABG,
post-operative AF conferred an eight-fold increased risk of
future AF and doubled cardiovascular mortality on long-
term follow-up.199 Follow-up rhythm monitoring, for
example with ECG or Holter monitoring is advisable in
this subset of patients particularly in the setting of symptom
development. There is emerging data on the use of implant-
able cardiac monitors for long-term monitoring of this subset
of patients. While implantable cardiac monitors allow contin-
uous long-term monitoring for arrhythmias and asymptom-
atic arrhythmias, the risk–benefit ratio is balanced by thearrhythmia detection rate beyond the immediate post-
operative period and level of invasiveness of the monitoring
device. Its routine use will depend on further results from
prospective medium to long-term studies.Patients with cryptogenic strokeCryptogenic stroke is defined as ischemic stroke of unde-
termined etiology.208 The diagnosis of cryptogenic stroke is
generally made by exclusion. Although cryptogenic stroke
includes few potential causes, such as paradoxical embolism
through a patent foramen ovale, atrial septal aneurysm, and
aortic arch atheroma, the majority of cases are thought to
be caused by cardio-embolism due to undetected paroxysmal
AF.205 For the diagnosis of cryptogenic stroke or a suspected
transient ischemic attack (TIA), patients should initially un-
dergo brain imaging. Diffusion-weighted MRI is more rec-
ommended than any other MRI sequence or CT as brain
imaging, except when contraindicated.204,205 Advances in
cardiac imaging techniques such as transoesophageal echo-
cardiography (TOE) have prompted the reassessment of
cryptogenic stroke because most cases are thought to be
embolic due to a cardiogenic source, mainly AF. Transoeso-
phageal echocardiography can easily detect a thrombus of the
left atrial appendage, particularly with contrast enhancement,
which cannot be detected using conventional transthoracic
echocardiography. Transthoracic echocardiography with
contrast could be useful to detect a left ventricular thrombus
(Figure 4).
The detection of permanent or persistent AF is relatively
easy, whereas that of paroxysmal AF is more difficult. Cur-
rent guidelines recommend the use of ECG monitoring
among patients with ischemic stroke including cryptogenic
When ischemic stroke is suspected
If cerebral embolism is suspected
If AF or intra-atrial thrombus is not detected
If any abnormality is not detected
If any abnormality is not detected
Medical interview and physical examination
Brain imaging
(Brain diffusion-weighted MRI scan or alternatively CT scan)
Assessment of cardiogenic source
24-h Holter ECG, long-term ECG monitoring, and echocardiography
Carotid artery imaging
(Doppler of Carotids, MR/CT angiography, or catheter angiography)
TEE, deep venous ultrasonography, aortic CT, specific blood test, and so 
on
Indication of ILR
Figure 4 Proceeding of evaluation for cryptogenic stroke. AF, atrial fibril-
lation; CT, computed tomography; ECG, electrocardiogram; ILR, implant-
able loop recorder; MRI, magnetic resonance imaging; TOE,
transoesophageal echocardiography.
Atrial fibrillation in athletes Class References
In athletes who participate long term in
endurance exercises with symptoms of
arrhythmia screening for AF is
recommended.
212
Risk assessment for AF risk in athletes
may include the duration and
intensity of exercise as a potential
modifiable risk factor.
213,214
e286 Heart Rhythm, Vol 17, No 9, September 2020stroke and TIA for whom transient (paroxysmal) AF is sus-
pected and no other causes of stroke are identified.205,206
First, 24-h Holter ECG is performed to detect the AF burden.
If undetected, other long-term ECG monitoring techniques
such as trans-telephonic ECG monitoring or cardiac event re-
corders (a symptom event monitor or a ILR) may be attemp-
ted as alternative methods. A meta-analysis indicated that a
longer duration of ECG monitoring is associated with an
increased detection of new AF when examining monitoring
time as a continuous variable. Studies with monitoring last-
ing 72 h detected new AF in 5.1% of cases, whereas moni-
toring lasting 7 days detected AF in 15% of cases.209 The
proportion of new diagnosis of AF was increased to 29.1%
with 3-months extended monitoring. Recently, smartphone-
based ECG recording systems have been developed and
conferred acceptable sensitivity and specificity of detecting
AF191 (see Wearables/direct to consumer section).
The use of an ILR is indicated for detecting the presence of
AF or arrhythmia burden that might cause ischemic stroke in
selected patients, for example those who are at higher risk of
AF development including elderly, patients with cardiovas-
cular risk factors or comorbidities. An ILR is a useful tool
for detecting arrhythmias. In the CRYSTAL AF study, AF
was newly detected in 8.9% of patients with an ILR by the
6th month compared with 1.4% among those receiving con-
ventional ambulatory ECG monitoring, increasing further to
12.4% by 12months compared with 2.0% in conventional
monitoring.80 A similar outcome was observed in the
EMBRACE trial, in which AF was newly detected in
16.1% of patients who received 30-day ILR compared with
3.2% who received ambulatory 24-h monitoring.210 A sys-
tematic review indicated that AF was newly detected in
nearly one-quarter of patients with stroke or TIA by sequen-
tially combining cardiac monitoring methods: 7.7% in phase
1 (emergency room), 5.1% in phase 2 (in-hospital), 10.7% in
phase 3 (first ambulatory period), and 16.9% in phase 4(second ambulatory period consisting of trans-telephonic
ECG monitoring, cardiac event recorders, and ILR), and
23.7% in the overall detection after all phases of sequential
ECG monitoring.207 Thus, if we ‘look harder, look longer
and look in more sophisticated ways’ we are more likely to
detect AF. It is possible that if we use clinical risk stratifica-
tion (e.g. the C2HEST score) to identify patients post-stroke
at high risk of incident AF, targeted intensive monitoring can
be applied.211How to assess high risk of atrial fibrillation in
professional athletesAtrial fibrillation risk in athletes—general
Paroxysmal or persistent AF is common in athletes and may
be autonomically mediated or triggered by other supraven-
tricular tachycardias.215 AF is the primary arrhythmia
observed in middle-aged athletes.216 AF in athletes tends to
be paroxysmal, vagally mediated, and highly symptom-
atic.213 The mechanism of increased AF risk at either end
of the physical activity spectrum likely includes autonomic,
structural, inflammatory, and fibrotic changes to the heart.
For example, increased vagal tone, which is often observed
in the endurance athlete, has been shown to result in a short
atrial refractory period, and thus initiates AF.217Atrial fibrillation risk in athletes—exercise paradox
Recent studies have observed a U-shaped risk relationship
of physical activity to AF. At one end of the spectrum, a
large observational study218,219 of people showed that those
at the lowest levels of physical fitness had a 5-fold increased
risk of AF.220 Increasing the physical activity of sedentary
patients could help reduce the risk or burden of AF.
Long-term endurance training, as well as a sedentary life-
style,221 increase chronic systemic inflammation, which in
turn could also facilitate AF.106 For example, one random-
ized study demonstrated that just 12 weeks of moderate-
intensity physical activity decreased the AF burden by
41%.222 Of the physically inactive with AF, the obese might
benefit the most from moderate levels of physical activ-
ity.220 In contrast, a meta-analysis of 655 endurance athletes
also demonstrated a five-fold increased risk of AF.212 Of
these studies, increased AF risk was generally only
observed with the highest levels of physical activity that
was maintained over a prolonged period of time.213,214
Nielsen et al Risk Assessment in Cardiac Arrhythmias e287One uniform explanation for the exercise paradox is that
both long-term endurance training and a sedentary lifestyle
increase chronic systemic inflammation.Atrial fibrillation risk in athletes—structural cardiac changes
Most studies have shown structural changes in endurance ath-
letes, which have resulted in the term athlete’s heart. These
changes include dilatation of all four heart chambers, increase
in left ventricular mass, and mild right ventricular hypertro-
phy.223 Studies show that moderate physical activity might
reduce inflammatory markers.224–226 Extreme levels of
exercise are a known cause of cardiac fibrosis, particularly in
hinge point locations of the heart, such as the right ventricle;
however, the significance of MRI-detected fibrosis remains
controversial.227 Athletes who experience higher levels of
fibrosis also have higher levels of coronary calcium.228 In
turn, fibrosis is a well-established risk factor of AF.163 In one
study, the fibrotic changes caused by vigorous exercise were
reversed after an 8-week period of physical activity cessa-
tion.229 Among young elite athletes, age, years of competition,
and echocardiographically measured parameters, including
left atrial anterior–posterior diameter and atrial strain, were
associated with higher AF risk.230,231 Although increasing
physical activity might reduce AF in sedentary patients,
decreasing physical activity levels in elite endurance athletes
may also reduce AF.215 Currently, the role of deconditioning
to lower AF risk in elite athletes for primary or secondary pre-
vention of arrhythmia requires prospective evaluation.Patients with inherited rhythm disease (long QT
syndrome/short QT syndrome/catecholaminergic
polymorphic ventricular tachyarrhythmia/Brugada
syndrome)Patients with inherited rhythm disease Class References
Patients with certain inherited
arrhythmia syndromes are at higher
risk for AF and benefit from symptom-
driven and periodic surveillance.
123
Evaluation should include non-invasive
symptom-driven surveillance for
patients at risk for AF and periodic
non-invasive surveillance for
asymptomatic patients.
232–234
EPS to determine atrial AF substrate or
susceptibility is not useful.
123Some patients with primary electrical sudden death syn-
dromes have an increased AF association, including Brugada
syndrome, LQTS, SQT, and catecholaminergic polymorphic
ventricular tachycardia (CPVT). These patients are at risk for
arrhythmia symptoms from AF and are vulnerable to AF con-
sequences such as pro-arrhythmia and inappropriate ICD
shocks.
Brugada syndrome is characterized by ST-segment eleva-
tion in the precordial ECG leads and increased risk of SCDdue to VF.235 Brugada syndrome is associated with a higher
incidence of SVTs, and AF is the most common SVT in these
patients.236,237 AF susceptibility has been described with pa-
tients harbouring mutations in SCN5A, CACNA1C and pa-
tients without an identified genotype,234,238 suggesting a
lack of genetic AF specific risk but AF may be more preva-
lent with more advanced disease.239,240 Importantly, AF
events can be pro-arrhythmic for Brugada syndrome pa-
tients123,241 and contribute to the high inappropriate ICD
shock rates for Brugada syndrome patients.241
Long QT syndrome is a genetically heterogeneous syn-
drome associated with mutations in 17 different genes with
some unique phenotypic characteristics based on genotype
and electrically results in prolonged repolarization and risk
for fatal ventricular arrhythmia torsade de pointes. While
generally, prolonged repolarization inhibits AF initiation and
this is the mechanism for Vaughn–Williams Class III anti-
arrhythmic drugs, rare patients with LQTS have also been
noted to haveAF.242,243 This has been limited to single case re-
ports and unverified, 1.7% of patients in a LQTS cohort, which
is a higher prevalence than the general population.133,244 Not
surprisingly, some genes associated with AF in LQTS have
overlap with familial AF: LQT1 (KCNQ1), LQT2
(KCNH2), LQT3 (SCN5a), and LQT7 (KCNJ2). However,
for potassium channels, in LQTS the genetic defect results in
‘loss of function’ in contrast to a ‘gain of function’ in familial
AF.245,246 It is less clear how prolonged repolarization results
in AF susceptibility but it may involve similar mechanisms to
torsade de pointes247 or perhaps dispersion of repolarization
and induction of early afterdepolarizations.248,249
From an electrical substrate standpoint, it is easier to un-
derstand why SQTS and CPVT are associated with AF. Short
QT syndrome is a rare disorder caused by a gain of function
of potassium channels encoded by KCNQ1, KCNH2, and
KCNJ2, causing a shortening of the action potential and man-
ifests in the atrium by a decreased atrial refractory period and
electrical substrate for AF.250–252 CPVT is an autosomal
dominant disorder associated with polymorphic VT and
bidirectional VT due to cellular calcium overload caused
by mutations in calcium handling genes.253–255 A
reciprocal condition can exist in the atria of patients with
CPVT with AF susceptibility and has been shown to be
more prevalent in patients with more dysfunctional
ryanodine receptor2 channels.256 It is also unclear how clin-
ically significant AF is for CPVT patients. However, the fail-
ure to recognize and treat AF can result in inappropriate
shocks, pro-arrhythmia, and death.232,233
These issues highlight the need for AF recognition, ICD
programming to reduce the risk of inappropriate shocks,
and preventative treatment. Because of the small cohort sizes
and lack of systematic studies, it is difficult to prospectively
estimate AF risk. Invasive EP studies evaluating atrial refrac-
tory periods, conduction time, and AF inducibility have been
inconclusive236,237 and either not systematically evaluated
in large populations or are contraindicated (LQTS and
CPVT).123 We support vigilant non-invasive surveillance
in these conditions. For patients with ICD, close follow-up
e288 Heart Rhythm, Vol 17, No 9, September 2020is needed to decipher and to adjudicate if atrial arrhythmias
are present and proactively increase the rate cut-off for VF
detection and turn SVT discriminators on, if available. Pa-
tients without ICD, but suggestive symptoms, should un-
dergo ambulatory monitoring and asymptomatic patients
should have surveillance monitoring done every 1–2 years.
Treatment is not the focus of this article, but it should be
recognized that many AADs can worsen the electrical sub-
strate for inherited arrhythmia patients (i.e. LQTS, Brugada
syndrome) and care should be taken when choosing antiar-
rhythmic drugs.How to assess risk for adverse outcomes in
patients with atrial fibrillation
Risk assessment for stroke/transient ischemic
attack/cognitive declineRisk assessment for stroke/TIA/
Cognitive decline Class References
A risk factor-based approach is
recommended for stroke risk
assessment in patients with AF.
8,257
Cognitive assessment should be
performed in AF patients where there
is suspicion of cognitive impairment.
258,259
Assessment of cognitive function may be
multifaceted, and cognitive
impairment screening by available
tools is just one component.
258
Risk reduction of cognitive
dysfunction and its comorbidities in
AF may include risk assessment for
vascular disease and/or Alzheimer’s
disease.
258,260
General health measures may reduce the
concomitant risks of AF and stroke,
with a putative benefit on cognitive
function.
1,2
Risk assessment for stroke/TIA after LAA
occlusion/ligation Class References
TOE after 6 weeks and if necessary after 1
year is useful for detecting peri-device
residual flow, incomplete appendage
ligation, or device-related thrombus
to identify patients at higher risk of
stroke.
271,272
Clinical features such as previous TIA/
stroke, persistent AF, low LVEF,
vascular disease, and early
discontinuation of anticoagulation
may be helpful to guide decisions
regarding imaging for device related
thrombus.
273,274
Multi-detector CT and cardiac CT
angiography have been found to be
equivalent to TOE to detect peri-
device flow.
275,276
After surgical occlusion or exclusion of
the left atrial appendage, imaging
may be useful to look for a residual
appendage and its function or a
residual leak after ligation to guide
decisions regarding anticoagulation.
261,277,278Patients with AF have increased mortality and morbidity
comparedwith non-AF patients andmay experience significant
adverse events. Stroke and thrombo-embolic events are well
known complications that can be avoided by oral anticoagula-
tion. Since the risk of individual patient differs significantly, an
individual risk assessment is necessary. Several stroke risk
scores, includingABC-stroke (age, biomarker, clinical history),
ATRIA (Anticoagulation and Risk Factors in Atrial Fibrilla-
tion), GARFIELD (Global Anticoagulant Registry in the
FIELD), and Qstroke have been proposed as support tools for
the decision on oral anticoagulation.261–264 However, the one
currently most widely applied and recommended by
international guidelines is the CHA2DS2-VASc risk scheme.
According to CHA2DS2-VASc, patients with score of 1 in
a male or 2 in a female should be considered for stroke
prevention strategies.265–268 Nevertheless, it has to be kept in
mind that no stroke risk schemehas perfect predictive accuracy.Another major adverse effect of AF is impairment of
cognitive function.258,259 Multiple risk factors for dementia
have been identified in the general population, including
modifiable and non-modifiable ones.269 Apart from these
AF-non-specific risk factors, AF may lead to cognitive
impairment by multiple mechanisms. These include
apparent stroke, silent stroke but also other mechanisms
that are independent of thromboembolism.270 A detailed
description of the association between AF and cognitive
impairment and possible preventive mechanisms has been
provided recently in an expert consensus document.258 In
terms of prevention of cognitive impairment in AF patients,
there is evidence that early and effective use of oral antico-
agulation in patients with stroke risk factors reduces the rate
of cognitive decline and currently, this represents the most
important preventive strategy. Consequently, the main risk
assessment for cognitive impairment in AF patients is the
assessment of stroke risk factors, preferably by use of the
CHA2DS2-VASc risk scheme that can guide the decision
on oral anticoagulation. When cognitive impairment is sus-
pected, brief screening tools such as General Practitioner
Assessment of Cognition (GPCOG), Mini Mental State Ex-
amination (MMSE) and Montreal Cognitive Assessment
(MOCA), and Informant Questionnaire on Cognitive
Decline in the Elderly (IQCODE) may be applicable.258 In
addition, more comprehensive assessments may be done af-
ter appropriate referral to a psychiatrist, geriatrician, or
neurologist.258Risk assessment for stroke/transient ischemic
attack status post-left atrial appendage occlusion/
ligation
Nielsen et al Risk Assessment in Cardiac Arrhythmias e289Left atrial appendage (LAA) occlusion/ligation using one
of several devices or surgical techniques has been devel-
oped as an alternative to anticoagulation in high-risk
patients with non-valvular AF.279–281 The maximum
experience has been with the Watchman device (Boston
Scientific), which has been found to be non-inferior to
warfarin in patients who are still candidates for short-term
warfarin treatment.282–284 Results of comparison between
LAA occlusion/ligation and NOACs are awaited. Current
guidelines recommend use of LAA occlusion as a
possible strategy in patients having contraindications to
long-term anticoagulation.261
The residual risk of stroke/TIA following LAA occlusion/
ligation can be related to procedural or patient related risk
factors. Among the procedure related factors, peri-device
leak, and device-related thrombus are important factors for
thrombo-embolic events in short and medium term after the
procedure. Stroke risk is significantly elevated in patients
in whom LAA ligation fails after surgical285 or percutaneous
approaches.286
Post-procedure surveillance is therefore important to
assess long-term risk of stroke and need for continued anti-
coagulation. These may be detected on TOE immediately or
after few weeks/months.271,272 Multidetector CT and car-
diac CT angiography have been compared with TOE and
found to be an effective alternative technique to detect
peri-device flow.275,276 Device-related thrombus is seen in
3–7% of patients after LAA closure, and leads to a 3–4
fold higher risk of stroke.273,274 Factors predicting device-
related thrombus are previous TIA/stroke, persistent AF,
low LVEF, vascular disease, and early discontinuation of
anticoagulation.273,274
If surgical LAA ligation fails or is incomplete, stroke
rates are significantly increased. Similarly, with percuta-
neous closure devices, residual LAA leaks were associated
with increased risk of thromboembolism in excess of that
associated with baseline risk factors or echocardiogram
findings.285Risk for heart failure incidence and progressionRisk for heart failure incidence and
prognosis Class References
Screening for AF in patients with HF
should be performed because of the
increased risk of adverse
cardiovascular outcomes in
combination more than the risk
conveyed by either disease state
alone.
287,288
Interval use of echocardiography and
arrhythmia directed monitoring for
development of AF-induced
cardiomyopathy and risk assessment
over time should be part of standard
follow-up for patients with AF.
289,290Atrial fibrillation and HF are conditions that coexist in
many patients, and sometimes it will be difficult to establish
if HF was the cause of AF or AF caused HF (tachycardia-
induced cardiomyopathy).287,291 In the Framingham study,
41% of patients with AF and HF developed HF first, 38%
developed AF first, and in the remaining 21%, AF and HF
occurred at the same time.288 AF is associated with a three-
fold increased risk of incident HF.292 In trials of patients
with chronic systolic heart failure, the prevalence of AF
was 4% in patients with Class I symptoms, 10–27% in pa-
tients with Class II–III symptoms, and 50% for those with
Class IV HF symptoms.290 Additionally, aging and the struc-
tural and neurohormonal changes in HF make the develop-
ment and progression of AF much more likely. The risks of
developing an AF-induced cardiomyopathy appear to be
related to the ventricular rate during AF and the duration of
AF. However, the precise incidence of tachycardia-induced
cardiomyopathy with AF, in patients with and without
SHD is unknown.
The mechanisms and pathophysiology of AF and HF
share several risk factors and common pathophysiologic pro-
cesses. Hypertension, smoking, obesity, diabetes, renal
impairment, sleep apnea, and CAD are all associated with
an increased risk of developing both HF and AF, and each
condition increases morbidity and mortality when associated
with the other. All types of HF (HFpEF or HFrEF) are asso-
ciated with an increase prevalence of AF.293,294 There are no
studies examining the role of monitoring to detect AF in
asymptomatic patients with HF or the management of AF if
detected. For patients with cardiac implantable electronic de-
vices, remote monitoring is a tool for determining AF burden
and is part of routine device follow-up. In patients with HF,
the risk of AF is increased by several mechanisms, remodel-
ling of atrial structure and increased fibrosis, ectopy pro-
moted by atrial stretch, increased spontaneous firing in the
pulmonary veins and alterations in calcium current handling
in the atrial muscle and sarcoplasmic reticulum calcium
content.289
The loss of atrial systole in AF impairs LV filling and can
result in left ventricular dilatation, decrease in myocardial
blood flow and increase in LV wall stress and end-diastolic
pressure. Atrial fibrillation can decrease cardiac output by
25% particularly in patients with diastolic dysfunction. The
mechanisms for reduction in cardiac output include loss of
atrial contribution to ventricular filling, increased mitral
regurgitation and decreased left ventricular filling time. The
irregular and rapid ventricular contraction in AF can lead to
LV dysfunction in an unknown percentage of patients and
in some patients a tachycardia-induced cardiomyopathy re-
sults.290 The irregular ventricular response also compromises
ventricular performance through changes in calcium
handling and reduced expression of Serca and phospholam-
ban phosphorylation. Management can vary widely accord-
ing to presentation and should be individualized since
treatments shown to be effective in one or other condition
alone, may give rise to safety or efficacy issues in an individ-
ual patient. Several recent trials have suggested a preferential
e290 Heart Rhythm, Vol 17, No 9, September 2020role for primary catheter ablation of AF in select AF patients
with HF compared to medical therapy alone.295–297
Treatment of AF by either rate or rhythm control may
reverse the cardiomyopathy and improve clinical HF
substantially in selected patients.Risk for death in atrial fibrillation patientsRisk for death in AF patients (including
risk for SCD) Class References
Clinical characteristics of the patient
including presence of advanced age,
cognitive dysfunction or dementia,
diabetes mellitus, hypertension, prior
stroke, vascular disease, and HF
should be used as important risk
markers of higher mortality in
patients with AF.
298,299Atrial fibrillation is associated with 1.5- to 2-fold higher
risk of all-cause mortality which may result from stroke,
HF, or SCD.261 Of the mortality associated with AF, only
1 in 10 deaths are stroke, and .7 out of 10 are cardiovascu-
lar.300 A multipronged strategy incorporating stroke preven-
tion, better symptom control, and cardiovascular risk
optimization is associatedwith improved outcomes, including
a reduction in mortality.3,4 Females with AF have slightly
higher mortality compared to male patients. Ethnic or racial
differences exist in mortality risk, with one study showing
highest risk in African Americans among all racial/ethnic
groups.301 Also, presence of comorbidities increases the risk
compared with ‘lone’ AF. Advanced age, renal failure, pul-
monary disease, andHF have been found to bemost important
risk factors for higher mortality in AF (Figure 5).298,299
Numerous risk scores have been designed to assess the
mortality risk in AF. The CHA2DS2-VASc score was de-
signed to assess stroke risk, but given it is a cluster of com-
mon risk factors for cardiovascular mortality also predicts
mortality risk.302 More complex clinical risk scores designed
to predict mortality, such as an integrated GARFIELD-AF
risk tool, statistically improves mortality prediction, being
superior to the CHA2DS2-VASc score.
303 All clinical riskLow Risk
Medium Risk
High Risk
heart failure, prior stroke and 
elevated levels of NT-proBNP 
and hs-cTnT
with significant 
diabetes, and  vascular disease
structural heart disease or 
significant
Figure 5 Mortality risk in patients with atrial fibrillation.scores only have modest predictive value (c-indexes 0.6–
0.7) but can always be statistically improved by the inclusion
of cardiac biomarkers, such as NT-proBNP and hs-TnT. Both
biomarkers (and others) have been found to be independently
associated with increased midterm mortality in AF patients
presenting to emergency room.304 Indeed, risk scores incor-
porating biomarkers have been proposed, such as the ABC-
death risk score, which utilizes age, biomarkers, and clinical
history. The ABC-death score achieved a c-index of 0.74
[95% confidence interval (CI) 0.72–0.76], while the
CHA2DS2-VASc score achieved a c-index of 0.58 (95% CI
0.56–0.61).305 However, the clinical usefulness of any risk-
prediction score for mortality has not been established, and
further validation studies are needed. Indeed, many risk
factors or biomarkers are based on measurements done at
baseline, and follow-up events occur many years later. Car-
diovascular risk is not static but changing with increasing
age and incident risk factor(s), thus repeat risk re-
assessment is more appropriate given that a change in risk
scores is more highly predictive of adverse outcomes.
Importantly, many biomarkers are non-specific, more
likely reflecting a patient with significant comorbidities and
significant underlying heart disease, and are predictive of
various endpoints apart from death, including stroke, heart
failure, etc.306,307 Indeed, biomarker-based scores like
ABC-death were derived from a highly selected clinical trial
cohort which was anticoagulated, and values were deter-
mined at study entry (baseline). Many biomarkers also
have a diurnal variation and inter/intra laboratory variability
and are predictive of non-cardiovascular outcomes. Real-
world studies investigating the usefulness of sequential
addition of biomarkers have shown limited value over con-
ventional clinical risk scores.10,308,309 Thus, statistically sig-
nificant improved prediction should not be confused with
clinically improved risk prediction. A balance is therefore
needed between (statistically) improved risk prediction and
simplicity or practicality for everyday clinical use in busy
clinical settings. In summary, any novel biomarker (or
biomarker-based scores) would need to be validated in large
non-anticoagulated cohorts. This is the starting point of risk
stratification with the newly diagnosed AF patient in any pa-
tient care pathway, and be simple, practical and adequately
validated to account for the dynamic nature of risk factors
and changes in drug therapies (including the use of antith-
rombotic drugs) over time.
Stroke resulting from AF has significant medium-term
mortality, which can be as high as 30.5% at 1 year.310 An
8-point GPS-GF score utilizing variables including Glasgow
Coma Scale, pneumonia, midline shift on brain images,
blood glucose, and female sex has been developed and was
found useful to predict 30-day mortality in patients with
AF-related stroke.311
Spontaneous AF is associated with an increased risk of
SCD in patients with Wolff–Parkinson–White (WPW) syn-
drome, HCM, and channelopathies such as Brugada syn-
drome.261 Several recent studies on HF and LVH and those
on the general population have reported that AF is linked to
Nielsen et al Risk Assessment in Cardiac Arrhythmias e291an increased risk of SCD.312–314 Mechanisms for SCD due to
AF are well understood for WPW syndrome or HCM, but are
unclear regarding other cardiac disorders. A meta-analysis
demonstrated a significant association between AF and SCD
in the general population as well as in patients with CAD,
congestive HF, HCM, Brugada syndrome, and implanted
rhythmdevices.315 In a nationwide cohort study fromTaiwan,
352 656 patients were identified. Among AF patients, age
75 years, congestive heart failure, hypertension, diabetes
mellitus, previous stroke/TIA, vascular diseases, chronic kid-
ney disease, and chronic obstructive pulmonary disease were
important risk factors for SCD or ventricular arrhythmias.316
A recent study suggested that optimal pharmacological treat-
ment, in addition to anticoagulant therapy, can reduce SCD
rates in patients with AF.317 Since pharmacological rhythm
control has so far been relatively ineffective in preventing
SCD in AF patients with low LVEF,318 catheter ablation
may be more appropriate for improving prognosis in patients
with AF.296 To assess the risk of SCD in patients with AF,
recognizing the presence of CAD, HF, LVH/HCM, pre-
excitation, Brugada syndrome, and implanted rhythm devices
is crucial. Examinations including 12-leadECG, echocardiog-
raphy, and other imaging modalities such as cardiac MRI are
useful for detecting various cardiac disorders. Electrophysio-
logical testing is useful for identifying risks in patients with
WPW syndrome and paroxysmal AF.
Risk of adverse outcomes in patients treated with
catheter ablationRisk of adverse outcomes in patients
treated with catheter ablation Class References
Patients that undergo an AF ablation
should be monitored closely in the
first 30 days after the procedure due
to a higher risk of neurological,
gastrointestinal, cardiovascular,
vascular and peripheral
complications.
319–324
Wolff–Parkinson–White syndrome
patients following radiofrequency
ablation may benefit from additional
follow-up due to a persistent elevated
risk of developing AF compared to the
general population.
295,325Radiofrequency (RF) ablation has emerged as a main thera-
peutic option for treatment of AF patients since 1998 after
the observation that AF mostly initiates from arrhythmogenic
triggers in muscular sleeves in the pulmonary veins.326 There
is abundant evidence that AF ablation is an effective method
for AF suppression leading to significant reduction of AF ep-
isodes and burden accompanied by substantial improvement
in symptoms and quality of life if performed in symptomatic
patients. For this reason, AF ablation is mainly recommended
by current guidelines as a method for symptom improvement
in symptomatic AF patients.261Post-ablation atrial fibrillation recurrence
Post-ablation AF recurrence is one of the most important and
frequent adverse outcomes, which occurs in 30–50% of
cases.327,328 In fact, although the acute success rate of AF cath-
eter ablation seems high, achieving a durable treatment efficacy
has remained a main challenge.261,328 Different factors
including female gender, older age, traditional cardiac risk fac-
tors, left ventricular dysfunction, increased epicardial adipose
tissue, myocardial fibrosis, and atrial enlargement have been
proposed as possible predictors of post-ablation AF recur-
rence.329–331 Moreover, diverse AF recurrence risk-prediction
scores, including APPLE, ALARMEc, ATLAS, BASE-AF2,
CAAP-AF, DR-FLASH, and MB-LATER have been intro-
duced; however, their integration into the daily clinical practice
needs further support by healthcare systems.332–341Other adverse outcomes
Apart from AF recurrence, according to the available real-
world data, around 5–15% of patients undergoing AF
catheter ablation experience complications, mainly during
the index hospitalization and early in the post-procedure
course.319–324 A variety of complications, including
neurological, gastrointestinal, cardiovascular, vascular and
peripheral, as well as pulmonary complications have been
reported to occur after ablation procedures.319–324,342–346
Although different modifiable factors such as metabolic
syndrome, hypertension, alcohol consumption, sleep apnea,
and obesity have been proposed to be related with
arrhythmia-free survival after catheter ablation,347–350 their
impact on the ablation adverse outcomes is not clear yet,
and requires further investigations.Mortality and morbidity
The impact of the ablation on hard clinical endpoints is much
less evident. Previous findings from observational studies
indicated a positive effect of the procedure on mortality
and morbidity.351 These, however, were not confirmed in
the recent large randomized Catheter Ablation vs Antiar-
rhythmic Drug Therapy for Atrial Fibrillation Trial
(CABANA) that had as primary endpoint a composite of
death, disabling stroke, serious bleeding, or cardiac arrest.295
In contrast, positive effects on hard clinical endpoints
including mortality have been reported in patients with HF.
In the CASTLE-AF trial, patients with impaired LVEF
,35% and previous ICD implantation who were treated
with ablation therapy had a lower rate of death from any
cause or hospitalization for worsening HF compared to pa-
tients undergoing medical treatment.296Stroke
Regarding the impact of AF ablation on stroke and in partic-
ular the validity of stroke risk schemes for stroke risk strati-
fication after ablation, observational data suggest a reduced
stroke risk after AF ablation and a possibly safe termination
of anticoagulation, at least in selected patients.352,353
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trials as the Optimal Anticoagulation for Higher Risk Patients
Post-Catheter Ablation for Atrial Fibrillation Trial (OCEAN)
(NCT02168829) and the Prevention of Silent Cerebral
Thromboembolism by Oral Anticoagulation with Dabigatran
After Pulmonary Vein Isolation for Atrial Fibrillation (ODIn-
AF) trial (NCT02067182). Until now, one randomized trial
showed that ablation therapy for AF in patients with impaired
LVEF was associated with significantly lower rate of death
from any cause and worsening HF.274 Subgroup recommen-
dations may change after the completion of trials studying the
effect of ablation on stroke and the need for anticoagulation.
Particularly in HF patients, it remains to be seen in which
subgroups of patients the data indicating mortality reduction
after AF ablation are applicable.Catheter ablation in Wolff–Parkinson–White patients
Careful attention must be given in WPW patients who under-
went RF ablation, as it was demonstrated that they had an
increased risk of AF at follow-up when compared to general
population, though an increased risk of death was not re-
ported.296,325
Risk of adverse outcomes in patients treated with
surgical Maze
The surgical Cox–Maze operation was introduced in 1987 to
treat patients with refractory AF.354 This surgical approach
carries more risk of complications than the catheter ablation
procedure, and is suitable for selected patients only. In this
setting, we can observe three different case-scenarios.Atrial fibrillation surgery
A simplification of the Cox–Maze procedurewas proposed by
replacing the ‘cut and sew’ lesions by different ablation de-
vices andminimally invasive access.355 In the recent years, bi-
polar RF clamping devices guided on a beating heart, by
thoracoscopic epicardial approaches have been intro-
duced.277,356 This evolution has allowed the implementation
of this surgery for stand-alone persistent and long-standing
persistent AF ablation, after an ineffective antiarrhythmic
drug treatment or a previous endocardial ablation failure
with a IIa (Level of Evidence B) indication.278 On another
hand, this invasive approach carries some potential risks that
need to be anticipated and discussed. Ideally, this step should
involve an arrhythmia team in order to discuss the risk–benefit
balance of the procedure on a case by case basis.357Surgical Maze in patients with concomitant heart surgery
An AF surgical ablation procedure is reasonable for selected
patients with AF undergoing cardiac surgery for other indica-
tions.261 In patients that may receive a concomitant Maze
procedure, a shared decision-making strategy should be
used with an AF heart team to make the best decision
available for the patient and their heart condition.357 Mortal-
ity or major morbidity was not affected by concomitant AFsurgery [adjusted odds ratio (OR) 1.00; 95% CI 0.83–
1.20], but pacemaker implantation was more frequent
(adjusted OR 1.26; 95% CI 1.07–1.49).358 Stiff LA syn-
drome was also reported after surgical Maze procedure, pre-
senting with dyspnoea, pulmonary hypertension, and
elevated left ventricular end-diastolic pressure attributed to
reduced LA compliance.359
Predictors of AF recurrence after surgery include left atrial
dilatation, older age, over 10-year history of AF, and non-
paroxysmal AF.360–364Stand-alone surgical Maze
A stand-alone AF surgical ablation procedure may be reason-
able for selected patients with highly symptomatic AF not
well managed with other approaches (e.g. after a failed cath-
eter ablation, longstanding AF, dilated left atrium).365 After
Cox–Maze IV stand-alone procedure, overall operatory mor-
tality was 1–1.8%, overall complication rate was 10%, 8%
required pacemaker placement, and 12-month freedom
from atrial tachyarrhythmias was 89% (78% without antiar-
rhythmic drugs).366,367Left atrial appendage exclusion or removal during surgical
Maze
The prospective randomized trial comparing the efficacy and
safety ofLAAexclusionor removalwith surgicalMazeproced-
ure is lacking. However, epicardial LAA Atriclip occlusion
showed a high rate of complete left atrial appendage occlusion
and reduces the incidence of stroke in patients with AF under-
going cardiac surgery.281 After surgical occlusion or exclusion
of the LAA, it is recommended to continue anticoagulation in
at-risk patients with AF for stroke prevention.261 If surgical
LAAligation fails or is incomplete, stroke rates are significantly
increased compared to patients with complete closure.285How to assess risk for ventricular
tachyarrhythmia in specific populations
Patients with ischemic heart disease
Ventricular tachyarrhythmia/ventricular fibrillation events
are closely related to the risk of SCD in patients with ICM.
For this reason, the risk of VT/VF is commonly used as a sur-
rogate for the risk of SCD. In addition, in ICM, myocardial
ischemia is the most common trigger for VF and SCD.
For primary prevention, our current approach to SCD risk
stratification relies mainly on the evaluation of LVEF: values
below 30–35% allow the identification of ICD candidates,
who are at highest relative risk of SCD. On the other hand, pa-
tients with a LVEF .35% account for the highest absolute
number of SCDs.368 For this reason, many researchers
emphasize that EF is an inadequate marker for detecting pa-
tients who are at high risk for SCD despite having a normal
or sub-normal EF. It seems also to have very limited value
to identify amongst patients with a low LVEF those who
will benefit the most from an ICD. In other words, many
Nielsen et al Risk Assessment in Cardiac Arrhythmias e293patients with EF 35% are unnecessarily implanted with an
ICD for primary prevention, while some others, having a
EF .35% and a high risk of VT/VF, are not protected. In
this setting, new markers are needed to optimize screening
and patient selection for ICD implantation. For secondary pre-
vention, SCD risk is significantly higher, and risk stratifica-
tion is certainly more standardized.61,74
Secondary prevention of ventricular tachyarrhythmia/
ventricular fibrillation in patients with ICMSecondary prevention of VT/VF in
patients with ICM Class References
ICM substrate and ischemic triggers for
VT/VF must be evaluated when
appropriate (coronary angiogram,
functional ischemic evaluation by
nuclear scan, stress-
echocardiography, or MRI).
54,70,71
Cardiac MRI with a LGE can be considered
in order to evaluate arrhythmogenic
substrate including myocardial
scarring to include in risk assessment,
and guide a possible VT ablation
procedure. This investigation should
be preferably performed before ICD
implantation to avoid artefacts due to
the presence of an implanted device.
369
Primary prevention of VT/VF in patients
with ICM and LVEF. 35% Class References
ICM substrate and ischemic triggers for
VT/VF must be evaluated when
appropriate (coronary angiogram,
54,70,71For more than 20 years, patients with a history of sustained
VT/VF have been recognized to be at high risk of recur-
rence.370 Nowadays, these patients are given a Class I (Level
of Evidence A) indication for ICD implantation.70 For this
reason, the practical usefulness of VT/VF recurrence risk
assessment is questionable, as additional testing is likely not
going to influence decision pathways (i.e. catheter ablation
or antiarrhythmic drug therapy as an alternative to ICD implan-
tation), and patient outcomes in a secondary prevention setting.functional ischemic evaluation by
nuclear scan, stress-
echocardiography, or MRI).
EPS and non-sustained VT evaluation
could be considered to improve VT/VF
risk stratification in patients with
relatively preserved LVEF, particularly
311,374,375Primary prevention of ventricular tachyarrhythmia/ventricular
fibrillation in patients with ICM and a left ventricular ejection
fraction 35%Primary prevention of VT/VF in patients
with ICM and LVEF 35% Class References
ICM substrate and ischemic triggers for
VT/VF must be evaluated when
appropriate (coronary angiogram,
functional ischemic evaluation by
nuclear scan, stress-
echocardiography or MRI).
54,70,71
Cardiac MRI with a LGE can be considered
in order to evaluate arrhythmogenic
substrate including myocardial
scarring to include in risk assessment
and guide a possible VT ablation
procedure. This investigation should
be preferably performed before ICD
implantation to avoid artefacts due to
the presence of an implanted device.
369Patients presenting with ICM, in NYHAClass II–III, with EF
35% after 3months of optimized heart failure pharmaco-
logical treatment, are given a Class I/A indication for ICD im-
plantation for the primary prevention of SCD.70 Nonetheless,
it is widely recognized that only a small subgroup of these pa-
tients will present with VT/VF during follow-up, and conse-
quently will benefit from the device. A better risk
stratification of these patients would be crucial to help iden-
tify those who would indeed benefit from an ICD.Most of the
numerous investigations assessed in this setting, like pro-
grammed ventricular stimulation (PVS), heart rate variability
(HRV), late ventricular potentials (LVP), baroreflex sensi-
tivity, QT interval dispersion, T-wave alternans, and heart
rate turbulence have been largely abandoned because none
of them have influenced routine clinical practice.46,73,371,372
However, some of these explorations, like T-wave alternans,
have shown some value for SCD prediction in ICM pa-
tients.42 It is still uncertain whether biochemical markers as
B-type natriuretic peptide and N-terminal pro-BNP will
prove useful in assessing risk for VT/VF. Cardiac MRI
with LGE should also help to improve VT/VF and SCD
risk stratification by analysing cardiac structure and myocar-
dial scarring.373 Finally, a recent randomized trial suggests
that assessment for hibernating myocardium performed
routinely is of no use to decrease the risk of SCD.68Primary prevention of ventricular tachyarrhythmia/ventricular
fibrillation in patients with ICM and left ventricular ejection
fraction. 35%in the convalescent phase (first 2
months) after an acute coronary
syndrome.
Heart rate variability (HRV), LVP,
baroreflex sensitivity, QT-interval
dispersion, T-wave alternans and
heart rate turbulence have not been
evaluated adequately in this
population for generalized use.
73,371,372This group of patients should be the priority for VT/VF risk
assessment: in absolute numbers, it represents by far the high-
est number of those at risk of VT/VF and SCD.368 In addi-
tion, these patients are currently non-protected, as they are
not targeted for ICD implantation in guidelines, due to their
LVEF value.70 In this setting, MRI with LGE could be an
e294 Heart Rhythm, Vol 17, No 9, September 2020option to better understand the diagnosis, prediction, and
treatment of VT/VF.369 This investigation could possibly
help improve VT/VF and SCD risk stratification by analysing
cardiac structure and myocardial scarring, particularly when
EF is relatively preserved. In this setting, a large prospective
trial documenting that treatment guided by MRI-based risk
stratification improves outcomes in this patient group is still
very much expected.373
Otherwise, the MUSTT Trial suggested the value of EPS
for improving the SCD risk stratification, in the subgroup of
ICM patients with a residual EF comprised between 30 and
40%.376
In addition, other non-invasive investigations like tissue
Doppler Imaging (TDI) seem also to be of potential value
in predicting VT/VF in ICM. Late diastolic velocity assessed
by TDI, particularly when detected in the inferior myocardial
wall, seems to be a sensitive marker of future VT/VF.374
Finally, it is well known that non-sustained ventricular tachy-
cardia (NSVT) is a marker of increased risk of VT/VF and
arrhythmic death. During the convalescent phase after an
acute coronary syndrome, NSVT seems to be associated
with an increased risk of cardiovascular death, most marked
within the first 2months after detection.375 The use of such
investigations could help to detect those patients at higher
risk of VT/VF, more particularly during the early phase after
an acute coronary event. Specific measures like prolonged
monitoring or use of wearable cardiac defibrillator could be
undertaken on an individual patient-case basis. However,
more solid data are needed to support such recommendations
broadly.Patients with inflammatoryPatients with non-ischemic heart failurePatients with non-ischemic heart failure Class References
MRI may be considered for further risk
stratification of sudden death in
patients with non-ICM who do not
otherwise meet an indication for ICD
implantation.
377
EPS may be considered for further risk
stratification of sudden death in
selected patients with non-ICM who
do not otherwise meet an indication
for ICD implantation.
377
cardiomyopathies Class References
In patients with non-ischemic heart
disease who present with ventricular
arrhythmias, use of cardiac MRI or
cardiac PET can help delineate
etiology of non-ICM, initiate etiology-
driven treatment, and evaluate
prognosis.
52,53,379Patients with non-ischemic HF represent a broad and
diverse group of patients including those with progressive
and infiltrative forms of cardiomyopathies. For this reason,
the risk of developing VT in non-ischemic HF is difficult to
accurately predict in this group of patients. Subsequent sec-
tions in this document will address specific conditions that
have unique risk profiles including inflammatory cardiomyop-
athies, congenital heart disease, ACM, and Chagas’ disease.
Prior investigations into identification of the risk of devel-
oping VT in non-ICM focused on the risk of SCD and the roleof the implanted defibrillator for primary prevention. The
DANISH trial61 reported no survival benefit from prophylac-
tic ICD implantation in the overall cohort. Implantable
cardioverter-defibrillator reduced SCD to half, and subgroup
analysis showed that in patients younger than 68 years, sur-
vival was prolonged with an ICD. Although pooled analysis
of the five primary prevention trials (DEFINITE, SCD-HeFT,
CAT, AMIOVIRT, COMPANION, and DANISH;
n5 2970) revealed that ICD therapy was superior to medical
therapy in patients with non-ICM with decreased cardiac
function, these trials were judged globally negative.378
In a limited number of studies outside of these clinical tri-
als, the role of EPS or non-invasive programmed stimulation
has revealed inconsistent results.377More recently, the role of
cardiac MRI for definition of scar and potential substrate has
emerged as a powerful risk stratification tool in observational
studies.49,379,380 Genetic testing is also useful in patients with
decreased cardiac function with conduction disturbance (i.e.
LMNA mutations).
In summary, non-ischemic HF includes a diverse group of
patients with reduced ventricular function due to cardiomy-
opathies from different etiologies, and at high risk for VT.
Reduced cardiac function remains a powerful predictor of
VT and appropriate ICD therapy in these patients as a pri-
mary prevention. Cardiac MRI and EP testing shows promise
in some subsets. Further characterization based on the type of
cardiomyopathy leading to HF shows the most promise for
accurate assessment of VT risk.Patients with inflammatory cardiomyopathiesInflammatory cardiomyopathies encompass a broad spec-
trum of disorders characterized by myocardial inflammation
as the primary cause of cardiac dysfunction. This includes viral
myocarditis (commonest cause), cardiac sarcoidosis, giant cell
myocarditis, autoimmune myocarditis associated with under-
lying connective tissue diseases, eosinophilic cardiomyopa-
thies, and Chagas disease (addressed in a separate chapter).
In patients who present with ventricular arrhythmias and
diagnosed with non-ICM, the incidence of inflammatory car-
diomyopathy may be as high as 50%.381 Therefore, it is
important to consider inflammatory cardiomyopathies as an
underlying cause, given that these conditions may benefit
from specific etiology-driven treatments. Infectious causes
of myocarditis include viral (e.g. parvovirus B19 and human
Risk for ventricular arrhythmias in
patients with congenital heart disease Class References
In the pediatric patient with CHD,
ventricular overload, surgical scars
and patches or baffles, ventricular
dysfunction, and previous conduction
defects are recognized risk factors for
VT.
391–393
In adult patients with CHD, older age at
surgery, poor hemodynamic status,
and prolonged QRS represent the most
common risk factors for ventricular
arrhythmias.
392–394
In adult patients with CHD, VTs are
mainly observed after correction of
tetralogy of Fallot (TOF) and left
ventricular outflow tract defects.
394–396
In patients with TOF, residual
hemodynamic lesions and ventricular
dysfunction represent the most
important risk factors for VT or SCD.
394–396
In patients with TOF, frequent PVCs, QRS
.180 ms, palliative systemic to
pulmonary shunts, syncope, atrial
tachycardia, decreased LVEF, dilated
right ventricle, severe pulmonary
stenosis or regurgitation, are risk
factors for sustained VT.
394–396
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cardiomyopathies, other cardiotropic viruses include entero-
viruses, adenoviruses, hepatitis C, and human immunodefi-
ciency viruses) and uncommonly bacterial and other causes
depending on the geographical area and immunosuppression
status. Myocarditis associated with connective tissue and
autoimmune diseases encompass systemic lupus erythemato-
sus, scleroderma, rheumatoid arthritis, dermatomyositis,
polymyositis, cardiac sarcoidosis, and giant cell myocarditis.
Drug reactions may also cause hypersensitivity myocar-
ditis.381,382 In cases of an established cause of inflammatory
cardiomyopathy, the focus should be on treating the underly-
ing inflammatory condition. In the case of cardiac sarcoid-
osis, retrospective series have shown that specific treatment
with immunosuppressive therapy can increase VT free
survival.52
Cardiac MRI scan is the gold standard for diagnosing
myocarditis and inflammatory cardiomyopathies. Edema,
hyperemia, and LGE form the diagnosis of acute myocarditis.
Further diagnostic information is gleaned from T1 and T2
mapping techniques. Although no specific LGE pattern on
MRI is diagnostic of cardiac sarcoidosis, LGE is most often
observed in basal segments, particularly of the septum and
lateral wall, and usually in the mid-myocardium and epicar-
dium of the myocardium.383–385
The presence of LGE is significantly associated with
increased risk of adverse cardiac events. The presence
of LGE on cardiac MRI was associated with increased
risk of ventricular arrhythmias and death by greater than
20 fold in patients with EF .35% and extracardiac
sarcoidosis compared to sarcoid patients without evidence
of LGE on MRI, and the burden of LGE was associated
with higher rates of death/VT.386 In a meta-analysis of
155 patients with systemic sarcoidosis who underwent
cardiac MRI for work-up of cardiac sarcoidosis, the pres-
ence of LGE was associated with hazard ratio of 31.6 for
death, aborted SCD, or appropriate ICD discharge and
provided superior prognostic information as to compared
to other clinical and functional characteristics, including
LVEF.51
In addition, the distribution of LGE confers important
prognostic information, with mid-wall anteroseptal LGE rep-
resenting a more malignant form compared to a sub-
epicardial inferolateral wall LGE pattern.387,388 Inflammatory
biomarkers, such as C-reactive protein, are typically lower in
this group with septal LGE, but biomarkers of myocardial
damage such as troponin are typically higher, suggestive of
a subset with less inflammation but greater myocardial injury.
F-fluorodeoxyglucose (FDG)-PET is advantageous for de-
tecting active inflammation in cardiac sarcoidosis, and a
mismatch of FDG and perfusion and involvement of the right
ventricle predicts adverse cardiac events and ventricular ar-
rhythmias, respectively.53 Endomyocardial biopsy is per-
formed in cases where a histological diagnosis is required
to confirm cardiac sarcoidosis or giant cell myocarditis,
with its yield enhanced by electrogram guidance. Active viralgenomes may also be identified by biopsy, which can differ
significantly from peripheral serological tests.382,389
Little data exist on how to assess risk of VT/VF in inflam-
matory cardiomyopathies. Besides EF, which is used for all
non-ischemic etiologies, no randomized studies have evaluated
other parameters or even EF as a predictor of VT in different
inflammatory cardiomyopathies. In particular, certain inflam-
matory cardiomyopathies may carry higher risk than others
(sarcoidosis vs. viral myocarditis). Risk of ICD therapy may
be as high as 15%per year in biopsy proven cardiac sarcoidosis
patients.390 Although randomized data on use of higher EF in
these patient populations is lacking, given risk of VT noted in
retrospective studies, use of MRI and cardiac PET to evaluate
etiology of non-ischemic heart disease is warranted, and treat-
ment of inflammation to reduce risk of VT is advised. Further-
more, cardiac PET andMRI can be used to assess for recurrent
inflammation or progression of disease on treatment.Patients with congenital heart diseaseVentricular arrhythmias in patients with congenital heart dis-
ease (CHD) may be observed in two different groups: the pe-
diatric age group and adults with repaired congenital defects
group.397 In the pediatric age, life-threatening VT is rare both
prior to and after surgery. Ventricular tachyarrhythmia is
seen in only 1.8% of children undergoing an EPS,391 is usu-
ally associated with structurally normal heart and most
frequently comes from the right outflow tract and left outflow
tract and sinuses of Valsalva.
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trophysiologic factors related to each disease state and associ-
ated therapeutic interventions play an important role in the
development of VT, with ventricular overload, surgical scars
and patches, baffles and conducts, ventricular dysfunction,
and previous conduction defects among the most relevant.392
In the early post-operative stage, Van Hare et al. reported
only 3 patients with VT out of 580 undergoing pediatric sur-
gery and the most important risk factor was the surgical pro-
cedure.391 Sustained VT may arise in the setting of
myocardial ischemia or infarction and may be facilitated by
disruption of the ventricular myocardium caused by scar due
to ventriculotomy, fibrotic tissue, or ventricular dilatation.393
In adult patients with CHD, VTs are mainly observed after
correction of tetralogy of Fallot (TOF) and left ventricular
outflow tract defects but may also arise in other defects as trans-
position of the great arteries with atrial switch, univentricular
hearts, double-outlet RV, and ventricular septal defects. Older
age at surgery, poor hemodynamic status, and prolongation of
the QRS represent the most common risk factors. In patients
with TOF, the correlation of residual hemodynamic lesions
and right ventricular dysfunction with risk of VT or SCD has
been extensively established.394,395 Potentially treatable resid-
ual hemodynamic problems, pulmonary hypertension, elevated
end-diastolic pressures, and reduced ventricular function should
be treated as part of the arrhythmia management. Particularly in
this group, frequent PVCs,QRS 180ms or more, palliative sys-
temic to pulmonary shunts, syncope, atrial tachycardia,
decreased LVEF, dilated right ventricle, severe pulmonary ste-
nosis or regurgitation are risk factors for sustained VT, and
inducible sustained VT correlates with increased risk of
SCD.396,398 EPS might be considered for risk assessment of
VT/VF in this group of patients with high-risk clinical charac-
teristics and frequent ventricular arrhythmias.327Patients with inherited arrhythmia diseases
(inherited channelopathies and inherited
structural diseases including arrhythmogenic
right ventricular cardiomyopathy)Risk for ventricular arrhythmias in
patients with inherited arrhythmia
diseases Class References
Patients with primary inherited
arrhythmia syndromes and
cardiomyopathies should undergo risk
stratification that integrates clinical
presentation, family history, and non-
invasive diagnostic testing.
123
Select patients with primary inherited
arrhythmia syndromes and
cardiomyopathies may benefit from
electrophysiologic testing to refine
non-invasive risk stratification.
399Patients with inherited arrhythmia disease are without doubt
at increased risk for ventricular arrhythmias, including SCD.The extent to which this is pertinent and predictable is
different for the various conditions.
The main primary inherited arrhythmia syndromes, i.e. the
‘channelopathies’ are LQTS, Brugada syndrome and
CPVT.400 Patients that are symptomatic (syncope, cardiac ar-
rest) at the time of presentation are at highest risk, with
arrhythmic syncope representing a sentinel sign of risk, and
resuscitated cardiac arrest reflecting the highest risk cohort.97
Despite major social impact on perceived risk, family history
is not of major importance in all three diseases.
In LQTS, clearly defined disease-specific risk factors are
the extent of resting QT prolongation, documentation of
arrhythmias and gene and even mutation specific associated
risk.401 In CPVT, the extent of the arrhythmic response of
an exercise test predicts events, including breakthrough symp-
toms on therapy.402 It follows that risk assessment requires a
baseline ECG and an exercise test in both conditions, with
potential value of ambulatory monitoring. Assessment should
include asymptomatic patients often identified during family
screening or after incidental unrelated medical evaluation.
In Brugada syndrome, there is uncontested agreement that
symptomatic patients (arrhythmic syncope, cardiac arrest) are
at high risk for SCD, requiring aggressive therapy with an
ICD in most circumstances. Risk stratification in asymptom-
atic individuals with a spontaneous type 1 ECG is much less
clear, involving a variety of ECG characteristics and potential
value of programmed electrical stimulation (PES).403,404
ECG parameters that have been associated with increased
risk include QRS fragmentation, early repolarization, Bru-
gada type changes in non-anterior precordial leads and a pos-
itive signal-averaged ECG. Programmed electrical
stimulation with a non-aggressive stimulation protocol may
be of importance, although the risk of an inducible patient
is only marginally different from a non-inducible patient.77
In LQTS, CPVT, and Early Repolarization syndrome, PES
is of no importance. The presence of a SCN5a mutation
may contribute to risk in Brugada syndrome.405 Early repolar-
ization syndrome, short-coupled idiopathic VF (SCIVF), and
SQTS are uncommon causes of cardiac arrest and sudden
death. Though the early repolarization pattern conveys a
small increase in risk, the only patients where the risk is sub-
stantive to consider intervention are those with prior cardiac
arrest or syncope with a positive family history. There are
no validated risk models in SQTS and SCIVF.
In the cardiomyopathies, i.e. the secondary inherited
arrhythmiasyndromes,riskstratificationisalsodiseasespecific.
In hypertrophic cardiomyopathy (HCM) septal thickness, the
hallmarkof the disease is an important contributor to risk.Other
risk factors include left atrial dimension, leftventricularoutflow
tract gradient (all echocardiographic parameters), the presence
of ventricular arrhythmias on ambulatory monitoring (Holter)
or documentation otherwise, symptoms (i.e. unexplained syn-
cope, palpitations associated with near syncope), demographic
factors (age in particular), and family history. All these factors
are included in theESCriskscore calculator,406which is readily
available in an online tool (http://www.doc2do.com/hcm/
webHCM.html), and applied after standard imaging, exercise
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calculator is not compelling, and consideration of imaging and
exercise blood pressure response parameters have also been
used in borderline cases. In inherited, i.e. non-ischemic, dilated
cardiomyopathy(DCM), thegeneticbackground isvery impor-
tant, withLMNA(LaminA/C) andPLN (Phospolamban) lead-
ing to highly arrhythmic substrates.123,407,408 Of course,
reducedLVEFand the presenceof ventricular arrhythmias dur-
ing ambulatorymonitoring are important risk factors aswell. In
arrhythmogenic right ventricular cardiomyopathy (ARVC or
ACM), symptomatic arrhythmic events identify the patient at
highest risk, andmajor risk factors include age,male sex, unex-
plained syncope, non-sustainedVT, number of anterior precor-
dial leads with T wave inversion, and severe right or left
ventricular dysfunction.409Hence, as for the other cardiomyop-
athies, echocardiographic imaging, and Holter monitoring is
required for risk assessment. In all cardiomyopathies, MRI is
becomingincreasingly important, inparticular toshowthepres-
ence of fibrosis (HCM, DCM, ACM) and assess left and right
ventricular function. Genetic testing should be considered in
anypatientwith a phenotype suggestingan inherited cardiomy-
opathy and inDCMwith a suggestive family history or onset at
an early age that is otherwise unexplained (i.e. not myocarditis,
sarcoidosis etc.). Genetic testing is largely for diagnosis, and
only informs risk when a high-risk form of cardiomyopathy is
diagnosed, such as PLN or LMNA.Risk stratification in patients with ACM, specified
for arrhythmogenic right ventricular
cardiomyopathyRisk stratification of ventricular
arrhythmias in ARVC Class References
In patients with ARVC, history of aborted
sudden death, sustained ventricular
arrhythmias, and severe right and/or
left ventricular dysfunction identify a
high risk of cardiac death.
410,411
In patients with ARVC, advice to not
perform high-level or endurance
exercise should be given.
412,413
Clinical factors including age, male sex,
unexplained syncope, non-sustained
VT, number of anterior precordial
leads with T wave inversion, and
genetic mutation status can be used
for prognostic stratification of
patients with ARVC.
410,411
In patients with confirmed ARVC, regular
Holter monitoring and imaging for
assessment of ventricular function
may be useful.
412,413
A detailed history of exercise intensity
and duration may be helpful in
patients with ARVC as exercise level
may represent a modified risk factor of
adverse cardiovascular events and
disease progression.
414In arrhythmogenic right ventricular cardiomyopathy
(ARVC or ACM), the most important features characterized
as the high arrhythmic risk include the electric instability (i.e.
sustained ventricular arrhythmia [VA]), genotype-positive,
extent of structural involvement, cardiac syncope, the pres-
ence of multiple mutations, and the history of competitive
or endurance exercise.410,411 In patients without prior VA,
an available online prediction model, derived from the largest
cohort of ARVC patients, using readily available clinical pa-
rameters was devised to estimate the risk of VA and to guide
the decisions of ICD implantation as primary prevention
(www.arvcrisk.com).415
There is a dose-dependent relationship between endurance
exercise and the disease onset and progression in confirmed
ARVC patients. Exercise restriction is recommended to pre-
vent disease progression and SCD in confirmed ARVC pa-
tients with ICD412 and genotype-positive relatives.413 In
general, high-level or endurance exercise is not recommen-
ded in confirmed ARVC patients or at risk.
Ambulatory ECGmonitoring is crucial to detect the PVCs
burden or the presence of non-sustained VT, which also pro-
vide prognostic information in ARVC.414 All positive criteria
of signal-averaged ECG non-invasively identifies the slow
conduction of myocardium and has been proven for risk strat-
ification in patients with suspicion or confirmed ARVC.416
Echocardiography and cardiac MRI provide accurate
measurements of right ventricular global and regional
dysfunction and right ventricular volume and regional/global
ventricular function, as the important variable for assessment
of right and left ventricular disease. The Task Force Criteria
did not include cardiac MRI measures of right ventricular
myocardial fat or LGE in order to risk stratify the
ARVC.417 In summary, abnormal cardiac MRI was an inde-
pendent predictor of clinical events with a cumulative effect
of the abnormalities including morphology, wall motion, and
fat/fibrosis in ARVC patients.416
An EPS may provide help distinguish ARVC from idio-
pathic right ventricular outflow tract (RVOT) VT. Addition-
ally, positive inducibility on program ventricular simulation
is not a perfect surrogate marker neither for ARVC diag-
nosis, nor the decision of ICD implantation.410,411 EPS
may be beneficial to identity patients that may benefit
from ablation. In this setting, EPS with high-dose isoproter-
enol may help differentiate patients with idiopathic VT or
ventricular premature beats from those with ARVC.418
The positive inducibility of EPS can predict any ICD ther-
apy, including VF, and can be an important parameter for
risk stratification in patients with ARVC.
ARVC is considered to have desmosome dysfunction. Ge-
netic causes of isolated or predominantly RV arrhythmia and
structural abnormalities are most commonly associated with
desmosomal gene variants. Positive genetic test contributes
up to 50% of the diagnosis of ARVC, however, in confirmed
ARVC patients, limited evidence of clinical actionable risk
stratification or use of management of disease. Several
gene variants have been reported in patients with left
ventricular or biventricular arrhythmia. Left ventricular
Table 3 Rassi score
Risk factor Points
NYHA Classes III or IV 5
e298 Heart Rhythm, Vol 17, No 9, September 2020dysfunction is most often present in patients with ARVCwith
pathogenic variants in Lamin A/C, or variants in the PLN and
TMEM43 genes, and followed by variants in DSP, DSG2/
DSC2.123,399,419,420Cardiomegaly (chest radiograph) 5
Segmental or global wall motion
abnormality (2D echocardiogram)
3
Patients with Chagas diseasePatients with Chagas disease Class References
The Rassi score is useful in assessing
risk of death in Chagas disease
patients.
421,422
In patients with syncope and a BBB,
an invasive EPS is useful in assessing
risk of sustained ventricular
arrhythmias.
423,424
When available, cardiac MRI with LGE
should be considered to evaluate for
arrhythmogenic substrate as part of a
risk stratification strategy in those
patients with cardiomyopathy.
425–428
Non-sustained ventricular tachycardia
(24-h Holter)
3
Low QRS voltage (ECG) 2
Male sex 2
Total points
Total mortality (%)
Risk5 years 10 years
0–6 2 10 Low
7–11 18 44 Intermediate
12–20 63 84 HighChagas disease is an infectious disease affecting 10 million
people around the world and 100 million more are at risk
of this infection. Due to migration, it is estimated 750 000 in-
fected carriers live in the USA or Europe.429,430 VA, espe-
cially sustained VT, is closely related to high mortality,
sudden death (SCD) happening in 17–50% of chronically
ill patients.431 Based on the identification of different risk
factors, Rassi et al. developed a mortality risk score
(Table 3).421 Patients with HF, NYHA Class III/IV and
NSVT on Holter and patients in NYHA Class I/II, with left
ventricular dysfunction and NSVT on Holter are at the high-
est risk of death and should be regarded as candidates for
aggressive therapeutic management.
Conversely, patients with an abnormal ECG (right or left
bundle branch conduction disorders) but in NYHA Class I/II
HF without left ventricular dysfunction or NSVT on Holter
are at lower risk of death. These patients should be followed
up annually or biannually. Between these two extremes,
some patients are at intermediate risk and their treatment stra-
tegies should be individualized.
SustainedVThasbeenreportedas themaincauseofsyncope
in patientswith non-documented recurrent syncope and bundle
branchblock(BBB).Inthesecases,anEPShasbeenrecommen-
ded for diagnosis elucidation.423 A finding of scar by LGE by
cardiac MRI in patients with Chagas disease is considered a
strongpredictor of a combinationof sustainedVTanddeath.432How to assess risk for adverse outcomes in
patients with ventricular tachyarrhythmia
Risk for appropriate and inappropriate implantable
cardioverter-defibrillator therapies
ICD therapies are associated with an increase in mortal-
ity.370,433–435 A single ICD shock is associated with a two- to
five-fold increase in mortality, and progressive heart failure
has been reported the most common cause of mortality amongthese patients.436–438 ICD therapies are classified as
appropriate, inappropriate, avoidable, and phantom.370,439,440
Approximately 12–17% of patients receive inappropriate
ICD shocks.433,436–438 Both appropriate and inappropriate
shocks area associated with an increase in mortality and can
significantly lower quality of life. Thus, identifying
predictors of ICD therapies may improve quality of life and
long-term outcomes in patients with ICDs.Appropriate shock predictors
A previous episode of sustained VT correlates with high
rate of appropriate shocks.441–444 A higher risk of
appropriate therapy was seen in a secondary prevention
ICD group when compared with a primary prevention
ICD group at 5-year follow-up, while the rate of inappro-
priate therapy was comparable.445 Several studies have
shown male sex as an independent risk factor for appro-
priate ICD therapies.446 Women are 30–50% less likely to
receive an appropriate shock,447–450 and this difference is
more pronounced among CRT-D recipients.451–453
However, most of studies have shown similar mortality
rates in both genders after ICD implantation.446–453 AF
is common in patients with left ventricular dysfunction;
the prevalence can increase up to 50%. Worsening AF
subtype increases the risk for both appropriate shocks
and overall mortality.454–457
Other risk factors implicated to increase the risk of
appropriate shocks are diabetes,454,458 elevated baseline
NT-proBNP and BNP,459 NSVT,456,460 left atrial diam-
eter,454,460 and impaired renal function.461 Data from
SCD-HeFT and MADIT II trials have found a higher
NYHA class, a lower LVEF, lack of use of beta-
blocker therapy and single-chamber ICD as significant in-
dependent predictors for appropriate ICD shocks.462 Data
from the Danish ICD Registry showed that LVEF ,25%
predicted an increased risks of both appropriate and inap-
propriate therapies.463
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The presence of supraventricular tachycardias, in particular
AF, has been reported as the most common risk factor for
inappropriate ICD shocks.437,455,456 Another risk factor asso-
ciated with inappropriate shock is younger age.459,461,462
Inappropriate shocks secondary to AF/atrial flutter are asso-
ciated with increased mortality while inappropriate shocks
related to sinus tachycardia or non-arrhythmic events like
noise, artefact, and oversensing have shown similar survival
as compared to those who do not receive a shock.464 Studies
have failed to establish the superiority of dual-chamber ICD
over the single chamber in reducing inappropriate
shocks.465,466 The Danish ICD Registry showed a two-fold
increase in the risk of inappropriate shocks associated with
a dual-chamber ICD.467 Device technologies and program-
ming, i.e. prolonged detection time, high rate programming,
and better discrimination algorithms have markedly reduced
the risk of inappropriate therapies.370,467,468Risk for heart failure incidence and progressionRisk for heart failure incidence and
progression Class References
Periodic monitoring of PVC burden (every 6
months) and LVEF and dimensions are
useful in patients with frequent,
asymptomatic PVCs and a normal LVEF
and dimensions.
469
PVC burden exceeding 20% is associated
with a higher risk of PVC-related
cardiomyopathy.
470–472
PVC burden lower than 10% is associated
with a lower risk of PVC-related
cardiomyopathy.
473,474
In patients with PVC-related
cardiomyopathy, absence of LGE on
cardiac MRI may be used to identify
patients with a favorable prognosis of
left ventricular systolic function
recovery.
475–477Tachycardia-induced cardiomyopathy is a reversible cause
of HF and impaired left ventricular function. Ventricular
rhythms causing tachycardia-induced cardiomyopathy
include VT, fascicular tachycardia, PVCs, and even persistent
rapid DDD pacing. Left ventricular systolic function
improves or normalizes and symptoms resolve, when tachy-
cardia is corrected or controlledwithmedication or pharmaco-
logic or non-pharmacologic rhythm control strategies.
Sustained monomorphic VT less commonly causes
tachycardia-induced cardiomyopathy as compared to sup-
raventricular tachycardias, since sustained VT is most
often associated with some form of structural heart
disease. When VT does lead to tachycardia-induced car-
diomyopathy, it is by definition idiopathic and most
commonly originates from the RVOT, left ventricularoutflow tract, or coronary cusps. If these arrhythmias
become persistent or high burden, they may cause revers-
ible left ventricular dysfunction.478
A single-center series reported that 11% of patients
who presented with frequent PVCs also had sustained
monomorphic VT and 7% of those patients had
tachycardia-induced cardiomyopathy. The presence of re-
petitive monomorphic VT was a significant predictor of
tachycardia-induced cardiomyopathy development, partic-
ularly when it was the predominant arrhythmia on 24-h
Holter monitoring.472
PVCs are very common and usually do not require treat-
ment in the absence of symptoms. However, in the clinical
setting of troublesome symptoms, or when PVCs trigger
polymorphic VT or cause cardiomyopathy, proper treatment
is critical. The concept of PVC-induced cardiomyopathy was
first proposed byDuffee et al.,471 who observed a small group
of patients with cardiomyopathy recover normal left ventric-
ular function after pharmacological suppression of frequent
PVCs.
Baman et al.470 reported on 174 consecutive patients
referred for PVC ablation, 54 of whom had depressed
left ventricular function. The authors concluded that
although PVC-related cardiomyopathy may occur in pa-
tients with less PVCs, “in the presence of a PVC burden
24%, it may be helpful to suppress the PVCs by cath-
eter ablation or drug therapy to avoid the development
of cardiomyopathy.” However, Aki Lee et al., demon-
strated a high rate of resolution of frequent PVCs among
untreated patients with normal left ventricular function
and minimal symptoms. A strategy of active surveillance
is appropriate for the majority of patients with frequent
idiopathic PVCs in association with preserved LVEF,
owing to the low risk of developing left ventricular sys-
tolic dysfunction and the high rate of spontaneous reso-
lution. Periodic monitoring of PVC burden and LVEF
and dimensions can be useful in patients with frequent,
asymptomatic PVCs and a normal LVEF and dimen-
sions.469
It has become clear that comparative effectiveness trials
are needed to understand what the best treatment approach
is for patients with frequent PVCs and cardiomyopathy. A pi-
lot multicenter study (PAPS: Prospective Assessment of
PVC Suppression in Cardiomyopathy) is ongoing to better
understand the prevalence of frequent PVCs and CM, and
prove the feasibility of a large-scale randomized clinical trial
(not yet published).479
Several circumstances have been associated with PVC-
induced cardiomyopathy, including the PVC burden, asymp-
tomatic status, duration of a high PVC burden, PVC QRS
width .150ms, interpolated PVCs, epicardial origin, and
male gender. However, no prospective longitudinal assess-
ments have been conducted that definitively prove their
causal relation to PVC-induced cardiomyopathy.480
The diagnosis of tachycardia-induced cardiomyopathy or
PVC-related cardiomyopathy can be challenging and the role
of imaging modalities in the characterization of myocardial
e300 Heart Rhythm, Vol 17, No 9, September 2020tissue as part of the diagnostic workup is limited.475 Cardiac
MRI with LGE can accurately identify the presence and extent
ofmyocardial scar and has become afirst-line non-invasive im-
aging modality for the etiologic assessment of primary cardio-
myopathies and/or left ventricular systolic dysfunction, and
could identify early stage of the structural heart disease.Risk for death in ventricular tachyarrhythmia
patientsRisk for death in VT patients (including
risk for SCD) Class References
Risk for SCD should be judged in each
patient on a case-by-case basis and
risk considered as a continuous
variable rather than a dichotomized
variable (high or low risk may
change).
71,481,482
Individual risk assessment needs to be
dynamic as the type and severity of
risks can change over time (repeated
measurements need to be made over
time).
483
Risk assessment may include
consideration of mode of death as the
relative risk of non-sudden, non-
cardiac death, sudden cardiac death,
and non-sudden cardiac death is
influenced by aging and worsening
cardiomyopathy and cardiovascular
risk factors.
369,484,485
Risk of adverse outcomes in patients
treated with catheter ablation Class References
The etiology and severity of
cardiomyopathy and inducibility of
arrhythmias after VT ablation are
useful in determining risk of
recurrence of VT after catheter
ablation.
491
Risk scores in combination with
procedural characteristics may be
useful for assessing adverse outcomes
associated with catheter ablation
of VT.
492–494Risk prediction of death in VT patients has used numerous
non-invasive and invasive markers including: clinical
markers, mode of initial clinical presentation (e.g. sustained
stable monomorphic VT, ventricular flutter, or VF), bio-
markers, ECG abnormalities (e.g. left bundle branch block),
heart rate variability, signal-averaged ECG, ambulatory
ECG-based frequency domain T wave, microvolt level-T
wave alternans, heart rate turbulence, heart rate deceleration,
QT dispersion, cardiac autonomic function, echocardio-
graphic evaluation of LVEF, left ventricular diameter, left
ventricular mechanical dispersion by tissue Doppler, strain
and velocity parameters to evaluate regional LV function, ex-
ercise testing to evaluate functional status, MRI to measure
scar burden, and EPS to assess for inducibility of VT. Most
of these tests and markers were applied to patients at risk
of SCD and not patients who already have VT. Thus, their
use for predicting death in a patient with VT is unknown.
The main sources of information about risk for SCD in pa-
tients with VT are from two studies from the era prior to wide-
spread ICD use,486,487 the control groups (patients who did
not receive ICDs) in the primary prevention ICD studies
(MUSTT, MADIT, MADIT II, SCD-HeFT, DANISH, DEF-
INITE, CABage-PATCH, IRIS, DINAMIT) as well as anal-
ysis of large data samples from registries since ICDapproval from Europe, Canada, and the USA.70,488 These
data have been extensively reviewed to better characterize
which variables predict the development of SCD and death
in high-risk patients. Data from secondary prevention studies
(AVID, CIDS, CASH) provide additional information about
risk of death in patients who have had VT. Another source of
information is the International VT Ablation Center Collabo-
rative Study Group which analysed a large group of patients
with VT (approximately 2000 patients from 12 international
sites) undergoing catheter ablation.489 Finally, a third useful
source of data is the Seattle Heart Failure model developed
by Wayne Levy and his colleagues who analysed data from
a large sample of heart failure patients to predict risk of death
and SCD as well as create a model for predicting benefit from
ICD therapy.490 This model has been prospectively validated
among five additional study cohorts of almost 10 000 heart
failure patients. It is important to recognize that the causes
of death can change over time. For example, the risk of death
in a patient with post-MI VT may be largely due to mechan-
ical problems (VSD, mitral regurgitation, heart failure) in the
first several weeks to months after MI and then 3–6months
later the risk of arrhythmic death may be much higher due
to matured scar-mediated substrate.
Based on these studies, the risk factors for death in VT pa-
tients include increasing NYHA class, old age, female gender,
electrical storm, frailty, diabetes mellitus, AF, chronic kidney
disease, chronic obstructive lung disease, peripheral arterial
disease, advanced HF, non-ICM, lower EF, multiple different
VT morphologies, use of hemodynamic support devices dur-
ing VT ablation, and poor functional status. These risk factors
can be divided into risk factors related to non-cardiac disease
(e.g. renal function, diabetes, COPD, peripheral arterial dis-
ease) which are powerful and determine mortality, and cardiac
risk factors (ischemic vs. non-ischemic etiology, multiplemor-
phologies of VT, EF, and functional status). There was an
interaction between variables, such as higher rates of both
VT recurrence and mortality, which was observed in patients
with lower EF and worse NYHA failure status.489,490Risk of adverse outcomes in patients treated with
catheter ablation
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patients who undergo catheter ablation of ventricular ar-
rhythmias is driven by patient-specific factors (comorbid-
ities), procedural factors, and presentation of the patient.
In a large retrospective multicenter registry, factors such
as low EF, chronic kidney disease, VT storm, and unmap-
pable VTs were associated with early mortality.495 As
mentioned above, male sex is associated with occurrence
of VT/VF and ICD shocks.496 As procedural factors are
often difficult to determine prior to the procedure, various
risk scores have been developed to assess risk of acute
hemodynamic compromise and/or death in patients under-
going catheter ablation of VT. Of these, a modified
version of the Seattle Heart Failure Model and PAINESD
score have been used in single-center and multicenter
retrospective studies to evaluate risk of acute hemody-
namic compromise or death post-procedure.492,493,495
The Seattle Heart Failure Model incorporates, amongst
other variables, age, EF, blood pressure, weight, gender,
HF medications, blood electrolyte, and hemoglobin levels
as well as NYHA to predict mortality. A modified version
of this model which incorporates VT storm and ICD
shocks was recently reported to be potentially more useful
in predicting 6months survival in patients who undergo
VT ablation.494 The PAINESD score incorporates pulmo-
nary disease, age, presence of ICM, NYHA, EF, VT
storm, and diabetes and assigns a score between 3 and
6 to each of these patient characteristics. In retrospective
studies, patients with a PAINESD score greater than 15
had a 24% risk of acute hemodynamic compromise and
a significantly higher risk of mortality.493,495 Use of these
risk scores can be important in discussion of risks and
benefits in patients undergoing catheter ablation and
may help determine need for hemodynamic support dur-
ing the procedure. However, larger multicenter prospec-
tive studies are required. It is important to note that
patients with lower EF and NYHA Class IV HF may still
benefit from successful catheter ablation of VT, and
freedom from VT after successful ablation is associated
with improved mortality.489,497
With regard to VT recurrence, in addition to patient
related comorbidities, large single-center and multicenter
studies have shown that the risk of VT recurrence is
driven by the underlying etiology, particularly in patients
with non-ischemic heart disease, even after adjusting for
other patient comorbidities.498–500 In particular, patients
with Lamin A/C cardiomyopathy, hypertrophic
cardiomyopathy, cardiac sarcoidosis, and valvular
cardiomyopathy appear to be at higher risk for VT
recurrence after catheter ablation as compared to
idiopathic DCM.491,498 In addition, location of scar seems
to determine risk of VT recurrence post-catheter abla-
tion.501 In this regard, endocardial ablation alone may
be insufficient in many non-ischemic cardiomyopathies.In arrhythmogenic right ventricular cardiomyopathy,
epicardial presence of scar can serve as the substrate for
VT and combined endo-epicardal mapping and ablation
or adjuvant epicardial ablation after endocardial ablation
is often required.502–505 Cardiac MRI with LGE can be
used in assessment of scar location and may be
beneficial in diagnosis and peri-procedural planning of
VT ablation.506
Retrospective studies have shown that inducibility of VT
at the end of ablation is associated with adverse outcomes,
even after adjusting for other patient comorbidities. Non-
inducibility of VT in ICM patients was shown to be associ-
ated with improved arrhythmia-free survival rates and
all-cause mortality,507,508 even after adjusting for other co-
morbidities. In addition, inducible clinical VT during non-
invasive programmed electrical ventricular stimulation
(PES) is associated with decreased 1-year VT free survival
as compared with those who are not inducible (,30% vs.
.80%).509
Patients who were non-inducible during non-invasive
PES after ablation had a VT recurrence rate of only 9% at
1 year of follow-up when both acute (at the end of the proced-
ure) and late (at 6 days post-procedure) programmed stimula-
tion were negative.510 Therefore, PES may be used to guide
redo ablation and address ICD programming.
Finally, although catheter ablation is generally per-
formed after the occurrence of ICD therapies, two clinical
trials reported the value of catheter ablation prior to or in
conjunction with ICD implantation. The Prophylactic
Catheter Ablation for Prevention of Defibrillator Therapy
clinical trial randomized patients with spontaneous ven-
tricular tachycardia or fibrillation and history of myocar-
dial infarction to ICD or ICD and catheter ablation. In
this trial, 30-day mortality was zero along with a signifi-
cant reduction in ICD therapies from 31% to 9% between
the control (ICD) and intervention arms (ICD 1 catheter
ablation).511 The Catheter Ablation of Stable Ventricular
Tachycardia before Defibrillator Implantation in Patients
with Coronary Heart Disease (VTACH) trial randomized
patients with history of myocardial infarction and stable
VT to catheter ablation followed by ICD implantation
vs. ICD implantation alone and showed that catheter abla-
tion reduced occurrence of VT or VF by 18% at 2 years of
follow-up. These data imply that in patients who receive
ICD for secondary prevention and have ischemic heart
disease, catheter ablation can be considered earlier, at
the time of ICD implantation, to reduce future ICD ther-
apies and prior to potential presentation with VT storm.512
The impact of early ablation (at the time of ICD implan-
tation) on mortality was the subject of the BERLIN-VT
clinical trial, early results of which have indicated a
lack of a difference in death or hospitalization for VT/
VF in the deferred group (ablation after occurrence of
third appropriate shock) vs. those who underwent
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It is important to note that in these studies, patients had
a history of VT or VF. In patients with ischemic heart dis-
ease undergoing ICD implantation for primary prevention
of sudden cardiac death, prophylactic substrate modifica-
tion of scar by catheter ablation requires further investiga-
tion. In the Substrate Modification Study, patients
randomized to ICD implantation plus VT ablation had
similar time to VT recurrence as those who underwent
ICD implantation only. However, catheter ablation at
the time of ICD implantation was associated with a
greater than 50% reduction in total number of ICD thera-
pies throughout the follow-up period.514How to assess risk for adverse outcome in
patients with other specific cardiac conditions
Patients with ventricular premature contractionsPatients with ventricular
premature contractions Class References
An evaluation of cardiac function
and screening for heart failure
symptoms should be
considered in patients with
frequent ventricular ectopy
(.10 000 PVCs within 24 h or
.10% over a more extended
timeframe).
515
An evaluation of cardiac function
and screening for heart failure
symptoms may be considered
in patients with frequent
multiform PVCs, PVCs with a
QRS duration. 150 ms or PVCs
with a coupling interval of
,450 ms.
516,517Frequent PVCs can lead to cardiomyopathy and HF,
and are associated with increased mortality.515 In addition,
in some patients with an inherited ACM, PVCs may be
the initial clinical manifestation that leads to this diag-
nosis. An initial case series describing four patients who
had reversal of cardiomyopathy after amiodarone success-
fully suppressed a high PVC burden has resulted in the
recognition for the potential reversibility of this condi-
tion.471 However, only a minority of patients with
PVCs will develop symptoms or adverse sequelae. The
factors that can potentially predict development of HF
and increased risk of adverse outcomes include PVC fre-
quency as well as characteristics of the PVC morphology
and timing of the PVC coupling interval.Premature ventricular complex frequency
In a large cohort of patients, increased PVC frequency was
associated with reduced LV function, a higher incidence ofheart failure, and a higher risk of death. Specifically,
compared to the lowest quartile of PVC frequency
(,0.002%), the highest quartile (0.123% to 17.7%) in this
cohort of patients with a structurally normal heart at baseline
had a 31% increased risk of death over a follow-up of
.13 years.515 Other studies correlating frequency with
PVC-induced cardiomyopathy suggested a threshold effect
observed at .20%, though there is no accepted cut-off that
appears to be protective.470,516 In a study of 239 consecutive
patients with apparently normal hearts, a PVC burden of.20
000 in 24 h was associated with a reduced LVEF, whereas
.10 000 but ,20 000 showed LV dilation with preserved
LVEF.518Premature ventricular complex morphology
In addition to PVC burden, the morphological features of
the PVC have been evaluated. The width of the PVC
QRS complex, perhaps reflective of dyssynchrony, has
been associated with increased risk of developing PVC-
induced cardiomyopathy.516,517 In these retrospective
studies, patients with a PVC duration of .150ms ap-
peared to require a lower burden for development of a car-
diomyopathy. A PVC duration of .153ms in patients with
a. 10% burden, was associated with an 82% sensitivity
and 75% specificity for subsequent development of a car-
diomyopathy. The presence of multiform PVCs has also
been associated with the development of new onset heart
failure.519Premature ventricular complex coupling interval
One mechanism of PVC-induced cardiomyopathy may be
due to ineffective mechanical contraction leading to adverse
remodelling, possibly related to the timing of the PVC. How-
ever, there are only a few small studies evaluating this. In a
retrospective cohort study of 510 patients, a PVC coupling
interval of ,450ms was associated with a reduced
LVEF.520 Another smaller study of 70 patients did not
show any association, though its power was limited.521
Another study specifically identified the presence of interpo-
lated PVCs regardless of coupling interval as associated with
reduced LVEF.522 A short PVC coupling interval may also
be an important determinant of VF, especially in patients
with genetic or acquired early or abnormal repolariza-
tion.42,523,524
While the promise of effective treatment for reversing
the potential adverse cardiac effects of frequent PVCs re-
mains a possibility, it remains unclear whether such pa-
tients can easily be identified. Most cardiologists accept
the dose–response relationship of PVC burden and
reduced cardiac function, although the precise threshold
for this effect remains unknown. There also is the poten-
tial for other factors aside from frequency alone, such as
PVC QRS duration and coupling intervals, to influence
adverse events associated with frequent PVCs.
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such as Wolff–Parkinson–White syndrome and
focal atrial tachycardiaPatients with supraventricular
tachyarrhythmia such as WPW syndrome
and focal atrial tachycardia Class References
EPS, with the use of isoprenaline, is
recommended to risk stratify
individuals with asymptomatic pre-
excitation who have high-risk
occupations/hobbies, and those who
participate in competitive athletics.
525–527
EPS should be considered for risk
stratification in asymptomatic pre-
excitation patients without high-risk
occupations or those who are not
competitive athletes.
525,527,528
Non-invasive screening with exercise
testing, drug testing, and ambulatory
monitoring may be considered for risk
stratification in asymptomatic pre-
excitation patients without high-risk
occupations or those who are not
competitive athletes.
525,527,528
High-risk features to consider at EPS
with or without catecholamine
challenge are accessory pathways with
an antegrade refractory period 250
ms, shortest pre-excited RR interval
during AF 250 ms, inducible
atrioventricular re-entrant
tachycardia, and multiple accessory
pathways.
525,529,530
Observation without treatment may be
reasonable in asymptomatic WPW
patients who are considered to be at
low risk following EPS, abrupt loss of
pre-excitation during exercise
testing, or due to intermittent pre-
excitation on a resting ECG or during
ambulatory monitoring.
525,527Patients with WPW may experience dramatic adverse
events including SCD due to VF.527 The estimate for the fre-
quency of SCD ranges up to 4% with more recent studies re-
porting a rate of 2%.525 Alarmingly, in approximately half of
the patients SCD is the first clinical manifestation of the syn-
drome rendering appropriate risk stratification essential.526
Risk assessment strategies have been recently reviewed in
the 2019 ESC Guidelines for the management of patients
with supraventricular tachycardia.531 Main risk factors for
the development of malignant arrhythmias and SCD in
patients with pre-excitation are: (i) a short anterograde refrac-
tory period of the accessory pathway with the optimal cut-off
reported to be at 250ms and (ii) inducible atrioventricular
reentrant tachycardia triggering pre-excited AF. A shortpre-excited RR interval during AF250ms and the presence
of multiple accessory pathways have been also reported as
risk markers. For these reasons, EPS is recommended for
risk stratification in subjects with asymptomatic ventricular
pre-excitation who either have high-risk occupations or are
competitive athletes. In patients without high-risk occupa-
tions or those who are not competitive athletes, EPS should
be considered for risk stratification of patients with asymp-
tomatic pre-excitation that can derive a prognostic benefit
from prophylactic catheter ablation of the accessory
pathway.531 Permanent Junctional Reciprocating Tachy-
cardia (PJRT) re-presents a rare form of atrioventricular
reciprocating tachycardia using a concealed accessory
pathway. The incessant behaviour of PJRT may result in
tachycardia-induced cardiomyopathy that usually resolves
after successful treatment by RF catheter ablation.
Non-invasive testing may also be helpful. Non-invasive
findings that identify a pathway not capable of maintaining
rapid conduction during AF include intermittent loss of con-
duction over the accessory pathway on the resting ECG or
during ambulatory monitoring, and abrupt loss of pre-
excitation during exercise testing.529,530
Focal atrial tachycardias are characterized by regular atrial
activation from atrial areas with centrifugal spread and can be
classified as sustained or non-sustained. Sustained focal atria
tachycardia in the adult population is usually associated with
a benign prognosis, although tachycardia-mediated cardio-
myopathy has been reported in up to 10% of patients referred
for ablation of incessant SVT.532 Non-sustained atrial tachy-
cardia is frequently found on Holter recordings and often
does not require treatment; however, we should consider
that patients with a high premature atrial complex burden
(.500/24 h) are at increased risk for developing of AF and
be educated on the symptoms of AF.533Summary
In clinical practice and for scientific purposes, cardiologists
and primary care physicians perform risk assessment in pa-
tients with cardiac diseases or conditions with high risk of
developing such.
The European Heart Rhythm Association (EHRA), Heart
Rhythm Society (HRS), Asia Pacific Heart Rhythm Society
(APHRS), and the Latin American Heart Rhythm Society
(LAHRS) set down this expert consensus statement task
force to summarize the consensus regarding risk assessment
in cardiac arrhythmias. Objectives were to raise awareness of
using the right risk assessment tool for a given outcome in a
given population, and to provide physicians with practical
proposals that may lead to rational and evidence-based risk
assessment and improvement of patient care in this regard.
A large variety of methods are used for risk assessment and
choosing the best methods and tools hereof in a given situa-
tion is not simple. Even though parameters and test results
e304 Heart Rhythm, Vol 17, No 9, September 2020found associated with increased risk of one outcome (e.g.
death) may also be associated with higher risk of other
adverse outcomes, specific risk assessment strategies should
be used only for the purposes for which they are validated.
The work of this task force is summarized in a row of
consensus statement tables.Appendix
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Supplementary data associated with this article can be found
in the online version at https://doi.org/10.1016/j.hrthm.2020.
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